TW505623B - Excitatory amino acid receptor modulators - Google Patents
Excitatory amino acid receptor modulators Download PDFInfo
- Publication number
- TW505623B TW505623B TW087107483A TW87107483A TW505623B TW 505623 B TW505623 B TW 505623B TW 087107483 A TW087107483 A TW 087107483A TW 87107483 A TW87107483 A TW 87107483A TW 505623 B TW505623 B TW 505623B
- Authority
- TW
- Taiwan
- Prior art keywords
- formula
- compound
- hexane
- group
- amino
- Prior art date
Links
- 108010027915 Glutamate Receptors Proteins 0.000 title claims description 9
- 102000018899 Glutamate Receptors Human genes 0.000 title claims description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 140
- 150000002148 esters Chemical class 0.000 claims abstract description 18
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 8
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 8
- ANUFAWHRSIJTHW-UHFFFAOYSA-N 2-methylheptanedioic acid Chemical compound OC(=O)C(C)CCCCC(O)=O ANUFAWHRSIJTHW-UHFFFAOYSA-N 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 36
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 15
- 150000001409 amidines Chemical class 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 230000002503 metabolic effect Effects 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- MWECKFISVWUYDM-UHFFFAOYSA-N bicyclo[3.1.0]hexane-2,6-dicarboxylic acid Chemical compound C1CC(C(O)=O)C2C(C(=O)O)C21 MWECKFISVWUYDM-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims description 2
- GOWMBYUZXIZENX-CAUSLRQDSA-N 1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hexadecylamino)pyrimidin-2-one Chemical compound O=C1N=C(NCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 GOWMBYUZXIZENX-CAUSLRQDSA-N 0.000 claims 2
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- WLYANNSIDDXEGE-GWGQIBMDSA-N (1s,2r,4s,5s,6s)-2-amino-4-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid Chemical compound OC(=O)[C@@]1(N)C[C@H](F)[C@@H]2[C@@H](C(O)=O)[C@H]12 WLYANNSIDDXEGE-GWGQIBMDSA-N 0.000 claims 1
- XHBZYLUDOIQPFQ-RGDLXGNYSA-N (1s,2s,5r,6r)-2-amino-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid Chemical compound OC(=O)[C@]1(N)CC(=O)[C@H]2[C@H](C(O)=O)[C@@H]12 XHBZYLUDOIQPFQ-RGDLXGNYSA-N 0.000 claims 1
- ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical compound CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract description 3
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract description 3
- 150000001408 amides Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 139
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 138
- 239000000047 product Substances 0.000 description 105
- -1 heteroaromatic radical Chemical class 0.000 description 87
- 239000011541 reaction mixture Substances 0.000 description 70
- 239000000243 solution Substances 0.000 description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 60
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 57
- 210000003169 central nervous system Anatomy 0.000 description 53
- 238000006243 chemical reaction Methods 0.000 description 52
- 238000000434 field desorption mass spectrometry Methods 0.000 description 49
- 238000011049 filling Methods 0.000 description 49
- 235000002639 sodium chloride Nutrition 0.000 description 47
- 239000000203 mixture Substances 0.000 description 46
- 229910001868 water Inorganic materials 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 238000004364 calculation method Methods 0.000 description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 38
- 239000002253 acid Substances 0.000 description 37
- 239000007787 solid Substances 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- 238000004458 analytical method Methods 0.000 description 32
- 230000002079 cooperative effect Effects 0.000 description 26
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000002585 base Substances 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 17
- 239000007789 gas Substances 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 239000012267 brine Substances 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- 150000003254 radicals Chemical class 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 14
- 125000002619 bicyclic group Chemical group 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 239000011737 fluorine Substances 0.000 description 12
- 229910052731 fluorine Inorganic materials 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 229910052757 nitrogen Chemical group 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000000123 paper Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000005277 cation exchange chromatography Methods 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 239000010949 copper Substances 0.000 description 8
- 239000006260 foam Substances 0.000 description 8
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 7
- 125000004494 ethyl ester group Chemical group 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 239000011593 sulfur Chemical group 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000003957 anion exchange resin Substances 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 6
- 239000000052 vinegar Substances 0.000 description 6
- 235000021419 vinegar Nutrition 0.000 description 6
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229940022663 acetate Drugs 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 150000001540 azides Chemical class 0.000 description 4
- 239000004305 biphenyl Substances 0.000 description 4
- 235000010290 biphenyl Nutrition 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 229910052681 coesite Inorganic materials 0.000 description 4
- 229910052906 cristobalite Inorganic materials 0.000 description 4
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 150000002431 hydrogen Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229910052682 stishovite Inorganic materials 0.000 description 4
- 229910052905 tridymite Inorganic materials 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 3
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000003257 excitatory amino acid Substances 0.000 description 3
- 230000002461 excitatory amino acid Effects 0.000 description 3
- 239000012025 fluorinating agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229940049906 glutamate Drugs 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 3
- 229940091173 hydantoin Drugs 0.000 description 3
- 150000007857 hydrazones Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 239000003810 Jones reagent Substances 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- YWWZCHLUQSHMCL-UHFFFAOYSA-N diphenyl diselenide Chemical compound C=1C=CC=CC=1[Se][Se]C1=CC=CC=C1 YWWZCHLUQSHMCL-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000005597 hydrazone group Chemical group 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 2
- 229950006874 kainic acid Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 2
- 229940067157 phenylhydrazine Drugs 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 229910052814 silicon oxide Inorganic materials 0.000 description 2
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- ZWVMLYRJXORSEP-LURJTMIESA-N (2s)-hexane-1,2,6-triol Chemical compound OCCCC[C@H](O)CO ZWVMLYRJXORSEP-LURJTMIESA-N 0.000 description 1
- PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
- WACNXHCZHTVBJM-UHFFFAOYSA-N 1,2,3,4,5-pentafluorobenzene Chemical group FC1=CC(F)=C(F)C(F)=C1F WACNXHCZHTVBJM-UHFFFAOYSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- AKUNSTOMHUXJOZ-UHFFFAOYSA-N 1-hydroperoxybutane Chemical compound CCCCOO AKUNSTOMHUXJOZ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical group CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
- XMLOHHSISONECN-UHFFFAOYSA-N 2,2-bis(ethylsulfanyl)acetic acid Chemical compound CCSC(C(O)=O)SCC XMLOHHSISONECN-UHFFFAOYSA-N 0.000 description 1
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- BIHSLTSGYFDSHV-UHFFFAOYSA-N 2,4-diaminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid Chemical compound NC1CC(N)(C(O)=O)C2C(C(O)=O)C12 BIHSLTSGYFDSHV-UHFFFAOYSA-N 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- JBPOZANHTUTRKU-UHFFFAOYSA-N 2-oxobicyclo[3.1.0]hex-3-ene-6-carboxylic acid Chemical compound C1=CC(=O)C2C(C(=O)O)C21 JBPOZANHTUTRKU-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
- 125000006291 3-hydroxybenzyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- GEEWLOREZHKJEL-UHFFFAOYSA-N 3-phosphonopentan-3-ylphosphonic acid Chemical compound CCC(CC)(P(O)(O)=O)P(O)(O)=O GEEWLOREZHKJEL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical class COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- TUXYZHVUPGXXQG-UHFFFAOYSA-N 4-bromobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1 TUXYZHVUPGXXQG-UHFFFAOYSA-N 0.000 description 1
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000015404 Amino Acid Receptors Human genes 0.000 description 1
- 108010025177 Amino Acid Receptors Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- OUTNJPNDBBOSEE-UHFFFAOYSA-N C(#N)OP(=O)(O)P(OCC)(OCC)=O Chemical compound C(#N)OP(=O)(O)P(OCC)(OCC)=O OUTNJPNDBBOSEE-UHFFFAOYSA-N 0.000 description 1
- BHJILMXPBXRVIF-UHFFFAOYSA-N C1=CC=CC=2C3=CC=CC=C3CC12.ClC1=C(C(=C(C=C1)Cl)Cl)Cl Chemical compound C1=CC=CC=2C3=CC=CC=C3CC12.ClC1=C(C(=C(C=C1)Cl)Cl)Cl BHJILMXPBXRVIF-UHFFFAOYSA-N 0.000 description 1
- QUTJZXHYWIELGA-UHFFFAOYSA-N COP(=O)OP(O)=O Chemical compound COP(=O)OP(O)=O QUTJZXHYWIELGA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical group F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- MMNKCVZNNOKIFH-UHFFFAOYSA-N [C-]#N.[Li+].[Na+].[C-]#N Chemical compound [C-]#N.[Li+].[Na+].[C-]#N MMNKCVZNNOKIFH-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 125000005157 alkyl carboxy group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 1
- JKJWYKGYGWOAHT-UHFFFAOYSA-N bis(prop-2-enyl) carbonate Chemical compound C=CCOC(=O)OCC=C JKJWYKGYGWOAHT-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- YAGCIXJCAUGCGI-UHFFFAOYSA-N butoxycarbonyl butyl carbonate Chemical compound CCCCOC(=O)OC(=O)OCCCC YAGCIXJCAUGCGI-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- SAFQZYRQIXIKDC-UHFFFAOYSA-N cyanomethylphosphonic acid Chemical compound OP(O)(=O)CC#N SAFQZYRQIXIKDC-UHFFFAOYSA-N 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- MWGDICRMMWNUSS-UHFFFAOYSA-N cyclopentane-1,1-dithiol Chemical compound SC1(S)CCCC1 MWGDICRMMWNUSS-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- HJSJHFXDUMCZEC-UHFFFAOYSA-N dichloroarsenic Chemical compound Cl[As]Cl HJSJHFXDUMCZEC-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000008252 erythrosides Chemical class 0.000 description 1
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- WTXWGJHLNCVWJH-UHFFFAOYSA-N ethyl 2-oxobicyclo[3.1.0]hexane-6-carboxylate Chemical compound C1CC(=O)C2C(C(=O)OCC)C21 WTXWGJHLNCVWJH-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 239000000928 excitatory amino acid agonist Substances 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-M gallate Chemical compound OC1=CC(C([O-])=O)=CC(O)=C1O LNTHITQWFMADLM-UHFFFAOYSA-M 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003823 glutamate receptor agonist Substances 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical class O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- VZGUURFINZVDHU-UHFFFAOYSA-N hexane-1,3,5-tricarboxylic acid Chemical compound OC(=O)C(C)CC(C(O)=O)CCC(O)=O VZGUURFINZVDHU-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- UOWWZCANEJESES-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;sodium Chemical compound [Na].COC(=O)C(C)=C UOWWZCANEJESES-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N methyl monoether Natural products COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- XGEGHDBEHXKFPX-NJFSPNSNSA-N methylurea Chemical compound [14CH3]NC(N)=O XGEGHDBEHXKFPX-NJFSPNSNSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- XXZNFWHGOMHWCO-UHFFFAOYSA-N n,n-diethylthiohydroxylamine Chemical compound CCN(S)CC XXZNFWHGOMHWCO-UHFFFAOYSA-N 0.000 description 1
- KYXVRQBHMGRRGY-UHFFFAOYSA-N n-[3-(3-bicyclo[2.2.1]heptanyl)prop-2-ynyl]-n-methylcyclohexanamine Chemical compound C1C(C2)CCC2C1C#CCN(C)C1CCCCC1 KYXVRQBHMGRRGY-UHFFFAOYSA-N 0.000 description 1
- SAVQQRYWWAGSQW-UHFFFAOYSA-N n-methyl-n-(trifluoro-$l^{4}-sulfanyl)methanamine Chemical compound CN(C)S(F)(F)F SAVQQRYWWAGSQW-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000003705 neurological process Effects 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- JVJQPDTXIALXOG-UHFFFAOYSA-N nitryl fluoride Chemical compound [O-][N+](F)=O JVJQPDTXIALXOG-UHFFFAOYSA-N 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- DMGNGMLLPVSMGC-UHFFFAOYSA-N phenyl butanoate phenyl propanoate Chemical compound C(CCC)(=O)OC1=CC=CC=C1.C(CC)(=O)OC1=CC=CC=C1 DMGNGMLLPVSMGC-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HPNURIVGONRLQI-UHFFFAOYSA-K trifluoroeuropium Chemical compound F[Eu](F)F HPNURIVGONRLQI-UHFFFAOYSA-K 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- SCHZCUMIENIQMY-UHFFFAOYSA-N tris(trimethylsilyl)silicon Chemical compound C[Si](C)(C)[Si]([Si](C)(C)C)[Si](C)(C)C SCHZCUMIENIQMY-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 108010002164 tyrosine receptor Proteins 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000009128 xihuang Substances 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/52—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/14—Compounds containing azido groups with azido groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/44—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups being part of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/383—Cycloaliphatic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
經濟部中央標準局員工消费合作社印製 505623 ----- Β7 五、發明説明() ~ 哺乳類中樞神經系統(CNS )中,神經脈衝之傳遞係受神 經遞質(係由遞送神經元釋出)與接受神經元上之表面受體 間之相互作用所控制。L -穀氨酸爲CNS中最豐富之神經遞 質其可調節哺乳類之主要興奮路徑,且稱爲興奮性胺基酸 (E A A)。對穀氨酸有反應之受體稱爲興奮性胺基酸受體 (EAA 受體)。參見Watkins及 Evans 之 Ann· Rev. Pharmacol. Toxicol·,21, 165 (1981) : Monaghan,Bridges 及 Cotman 之 Ann. Rev. Pharmacol. Toxicol·, 29,365 (198 9 ) ; Watkins. Krogsgaard-Larsen 及 Honore 之 Trans· Pharm. Sci·, 11, 25 (1 990 )。興奮性胺基酸具相當之生理學重要性,其在各種 生理過程中扮演著其角色,如長期效能(學習及記憶)、突 觸可塑性發展運動控制,呼吸,心血管調節及感覺認知。 興奮性胺基酸受體分類成兩·大類。直接偶合至神經元細 胞膜中(1%離子槽道開口之受體稱爲”趨離子性”,此類受 體又次分成至少三個次類’係藉選擇性興奮劑N _曱某_ d _ 天冬氨酸(NMDA)、κ -胺基-3-羥基-5 -甲基異气哇-丙 酸(AMPA )及:红藻氨酸(K A )之去偏極化作用加以定義。第 二大類受體爲G -蛋白質或第二種信使鍵聯之"代謝營養,,興 奮性胺基酸受體。此第二類係偶合至可引致增強之碍酸肌 醇水解作用、磷脂酶D或C活化作用之複數個信使系统上, 可增加或減少c-AMP形成及改變離子槽道功能。Sch〇epp AConn. Trends in Pharmacol.-Sci., 14,13 (1993 )。兩嘴為 體似乎不僅可沿著興奮路徑調節正常之突觸傳遞,亦可參 與生命發展及整個生命期間之变觸連,結之改質作用。 -4- 本纸張尺度適用中國國家標準(CNS ) A4規格(210X 297公籍) ' '^- (請先閱讀背面之注意事項再填寫本頁) 、11 505623 A7 B? 五、發明説明() .
Schoepp, Bockaert 及 Sladeczek,Trends in Pharmacol. Sci 11,508 (1990) : McDonald 及 Johnscm,Brain Research (請先閱讀背面之注意事項再填寫本頁)
Reviews, 15, 41 (1990)。 興奮性胺基酸受體之過度或不適當剌激將因已知爲興奮 毒性之機制作用而引起神經元細胞損傷或喪失。此過程已 被建議可調節神經元於各種狀況下退化。此種神經元退化 之醫學結果使該等退化神經學過程之重要治療目標減退。 代謝營養之毅氨§父受體爲高度異種群之穀氨酸受體,其 键聯至複數個第二信使路徑。該等受體之功能係調節穀氨 酸之哭觸前釋出及神經元細胞對穀氨酸激發作用之突觸後 敏感性。調節該等受體尤其是穀氨酸之興奮劑及拮抗劑之 功能之化合物可用以治療急性及慢性神經退化病況,及可 作爲抗精神劑、抗搐搦、止痛、抗焦慮、抗抑鬱及抗嘔吐 藥劑。 國際專利申請案公告號wo 96/05 175揭示作爲代.謝營養 穀氨酸受體興奮劑之化合物2-胺基雙環[3. ίο]己烷-2,6- 二叛酸及其鹽及其酯。 -、 本發明提供一種下式之化合物: 經濟部中央標準局員工消費合作社印製 國 中 用 適 度 尺 張 紙 本
505623 A7 B*7 五、發明説明( 經濟部中央標準局員工消費合作社印製 其中= (a) R 代表氟、XOR3、XNR4rJ CN或P〇3 R26且代表氫或 (b) R及R各代表氟:或 (C)R^R2合而代表=〇、二NOR7或= cr8r9 :或 (d) '及R之代表胺基及另一個代表幾基:或 (e) R1 代表 N3、(CH2)mC〇〇R3a NHC〇NHR3b或 NHs〇2R、R^表氫或-m 3 2、 (f) R1 及 R2 合而代表=CHC〇〇R3b、 二 CHCN :及 L_3R2 或 /代ί氫原子:(c“)垸基:U埽基:(C“)块 ,:,情況取狀芳族基:視情況取代之雜芳族基:心 一 雉基,與一或兩個單環芳族或雜芳族基 稠合t非芳族單環碳環美·愈 力 达加人、t 衣人表基.Μ或兩個單環芳族或雜芳族 基铜合(衫族單環雜環基;或經卜2或3個各選自下列 之^代: (C3-6)晞基或υ块基;視情 況取代〈方咚基、視情況取代之雜芳族基、非以 基、非芳族雜環基、與一或兩個單環芳族或雜,:: 之非芳族單環竣環基及與—或兩個單環芳族或 合之非芳族單環雜環基:土。 --------— (請先閲餐背面之注意事項再填寫本頁) 、11
R
R 3 b 及R3、R3定義: ( X代表化學鍵、c Η 2或c〇-: m代表1至3之整數: R 4代表C〇R10或如R 3定義:
• I 1 - I I - 505623 A7 B7 五 發明説明( 經濟部中央標準局員工消費合作社印製 H5、r7、R8、R9 及 R1。如 R3 定義: R6代表氫或(匸1-6)’丨充基’及 R6aw R6定義: 或其無毒性易代謝酯或酿胺:或其醫藥可接受性鹽。 式I化合物爲代謝營養毅氣故受體功能之調節劑,尤其是 在代謝營養穀氨酸受體之穀氨酸之興奮劑或拮抗劑。 因此,依據另一目的’本發明提供一種於包含人類之哺 乳類中調節代謝營養之毅氣受體功能之方法,包括投與 有效量之式I化合物或其無毒性易代謝酯或醯胺,或其醫藥 可接受性鹽。 - 依據另一目的,本發明係提供如上述定義之式I化合物用 以製造供調節代謝營養穀氨酸受體功能之醫藥之用途。 須了解式I化合物含有至少4個不對稱碳原子:3個在環丙 少元上及1個或2個在橡戊坑5衣上。亦須了解式中r 1及r 2合而 代表=N〇R 7之式Ϊ化合物可呈順式或反式態,及式.中r 1及 R2 合而代表二CR8R9、=CHC〇〇R3b、=CHp〇3R26a 或 二CHCN之式1彳匕合物可呈(E)或(z)態。本發明包含所有立 體異構態之式I化合物’包含個別對映異構物及其混合物。 本發明亦包含所有物理態之式I化合物,包含結晶之溶劑 化物。 較好式I化合彳^具有下列所示之組態丨a或丨b : 本纸張尺度適用中國國家標準(CNS ) Λ4規格(210X 297公趁) (請先閱讀背面之注意事項再填寫本頁) 五、發明説明(
la Μ 111 I -I ? - 1=—
lb 經濟部中央標準局員工消费合作社印製 有説明,否則本文所用之"燒基"一詞 ΓΓΓ :6)燒基有用之實例包含7c一基如ΐ 基、乙基、丙基、異丙基、丁基及異丁基。 (C3-6)晞基包含(C:34)烯基如烯丙基。 (C3 _6)炔基包含(C3 _4)炔基如丙炔基。 冰万基包含含1至4個選自氧、硫及氮之雜原子之5 _ 6員 芳族環及含1至4個選自氧、硫及氮之雜原子且與笨環或含 1至4個選自氧、硫及氮之雜原子之5 _6員環稠合之5_6員所 構成之雙環基。雜芳族基實例爲呋喃基、嘧吩基,、巧唾 基、異呤唑基、4唑基、異嘧唑基、咪唑基、嘧啶基、苯 幷吱喃基、幷Ρ塞吩基、苯幷咪峻基、苯幷U号唾基、苯弁 邊σ坐基及W嗓基。 芳族基包含苯基及多環芳族碳環如卜莕基或2 -萘基。 於”視情況取代之雜芳基或芳基”一詞中所用之”視情況取 代π表示可存在一,、二或多個取代基,該取代基係選自當存 在於式I化合物中時不妨礙式]Η匕合物作爲代謝營養毅氨酸 受體功能之調節劑之功能之原子及基。 可存在於視情況取代之雜芳基或芳族基/之原子及基之實 -8 - 本纸張尺度適用中國國家標準(CNS ) Α4規掊(210X 297公t ) -----— (請先閱讀背面之注意事項再填寫本頁)
、1T 505623 A7
El 五、 發明説明( 經濟部中央標準局負工消費合作社印製 例爲胺基、蠢基、硝基、鹵素、(C 1 _ 6 ) 基、(C 1 - 6 ) *元氧 基、(Cu)烷硫基、羧基、(Ci·6)烷氧羰基、胺甲醯基、 (Cu)烷醯胺基、(Ci_6)烷磺醯基、(Cu)烷磺醯胺基、 (C 1 · 6 ) fe SS基、冬基、冬氧基、冬硫基、冬靖®③基、冬石哭 醯胺基、甲苯磺醯胺基及(Ci-6)氟烷基。特別有用之實例 爲胺基、羥基、硝基、氟、氯、溴、碘、曱基、甲氧基、 甲硫基、羧基、乙醯胺基、曱磺醯基、甲磺醯胺基、乙醯 基、苯基、苯氧基、苯硫基、苯磺醯基及三氟甲基。 視情況取代之芳族基之有用實例爲1 -莕基、2 -莕基、苯 基、2 ·聯苯基、3 -聯苯基、4 -4#苯基、2 -羥苯基、3 -羥笨 基、4 -羥苯基、2 -氟苯基、3 -氟苯基、4 -氟苯基、2,4_-二 氟苯基、3,4 -二氟苯基、五氟苯基、2 -氯苯基、3 -氯苯 基、4 -氯表基、2,4 -二氯苯基、3,4 -二氯苯基、3,5 -二氯 苯基、2 -溴苯基、3 -溴苯基、4 -溴苯基、2 -曱基苯基、3 _ 甲基苯基、4-甲基苯基、2-甲氧苯基、3-甲氧苯基、4 /甲 氧苯基、2,3 -二甲氧苯基、2,5 -二甲氧苯基、3,4 -二甲氧 私基、3,5 -二一甲氧苯基、2 -三氟甲基苯基、3 -三氟曱基笑 基、4-三氣曱基苯基、2 -敦-3-三氟曱基苯基、3-三氣甲 基-4·氟苯基、3 -三氟甲基-5-氟苯基、2 -氟-5-三氟甲| 冬基、2 -冬氧本基、3 -表氧苯基、3 -幾苯基及4 -幾苯美。 ,,非f族碳環,棊V,,一詞包含單環基,例如(Ch1G)環燒基如 環丙基、環丁基、環戊基、·環-己基、環庚基、環辛基、環 壬基或環癸基,及稠合之多環基如1 -金剛烷基或2 ·金剛嫁 基、1 -莕燒基、2 -苔烷基、4 a -莕烷基、雙環[3 3 〇 ]辛 (請先閲—背面之注意事項再填寫本頁) 衣 、11 -9- 505623 一 B7 經濟部中央標準局員工消费合作社印製 五、發明説明() 1-基、-2 -基或-3 -基、雙環[4.3.0]壬-1-基、-2 -基、-3-基或-7 ·基、雙環[5 . 3 · 0 ]癸-1 -基、-2 -基、-3 -基、-4 -基、-8 _基或9 -基及雙環[3 . 3 · 1 ]壬-1 -基、-2 -基、-3 -基 或-9 -基。 ’’非芳族雜環基”一詞包含含1或2個選自氧、硫及氮之雜 原子之4 -至7 -員環,例如p丫丁咬-1 -基或-2 -基、p比洛。定-1·基、-2 -基或-3-基、六氫p比咬-1-基、-2 -基、-3 -基或-4 -基、:T?鼠叶庚因-1 -基、· 2 -基、-3 -基或-4 _基、ί篆·玉冢 丁 fe-2 -基或-3-基、四氫咬喃-2-基或-3-基、四氫ρ比喃-2 -基、-3 -基或-4 -基、六氫噚庚因-2 -基、 3 -基或-4 -基、硫雜環丁烷-2 -基或-3 -基、四氫4吩-2 -基或-3 -基、 四氫硫p比喃-2-基、-3-基或-4-基、六氫嘻庚因-2-基、 -3-基或-4-基、7^氮卩比呼-1-基或-2-基、嗎淋-1-基、-2-基或-j -基、嗎”林-1 -基、-2 -基或-3 -基、四氮續咬-1; _ 基、-2 -基、-4 -基或-5-基、味峻淋-l -基、-2 -基或-4-基、味哇淋口定-1 -基、-2 -基或-4 -基、17咢口坐淋-2 -基、-3 -基、-4 -基或'5 -基、17号峻p休咬-2-基、-3 -基、-4 -基或- 5-基、4唑啉-2 -基、-3 -基、-4 -基或-5 -基、或嘧唑啉啶-2 -基、-3 -基、-4 -基或-5-基。 ”與一或兩個單環芳族或雜芳族基稠合之非芳族單環碳環 基” 一詞包含與,,苯環或含1至4個選自氧、硫及氮之雜原子 r (芳族5 - 6貝壤稠合足(C 3 T 1 〇 )餐燒基,如印滿基、 1 , 2,3 , 4 -四氫莕-1 -基或-2 -基、5 , 6 , 7,8 -四氫喹啉-5 -基、-6-基、-7-基或-8-基、5,6,7,8-‘氫異喳啉-5-基、 -10- (請先閲讀背面之注意事項再填寫本頁) 本纸張·尺度適用中國國家標準(CNS ) A4規格(210X 297公釐)
Λ發明説明( -6 -基、-7 -基夺並 -基、*基或;二、四氯苯幷喧吩I基、 +基、二笨幷:幵[2.'6·7]環庚烷-1-基或 游基。 [一 ·6·7]^·4-埽小基或冰基,或9- 與或兩個單環芳族或雜環 環基”一詞包含盥贫γ 4、人 W 口心非万狹早環雜 子之芳族5-6員環::ί:^4個選自氧、疏或氮之雜原 子之4至7員環,如2 口3〜/二2個逐自氧」硫或氮之雜原 基、咕嘲-9-基、】2:PtffP比喃_2_基-、-3-基或-4- 1,2,J,4 -四虱 4 p林-i _ 基 或-4_基、9 1〇 一与γ、 廿 2_基、·3-基 ,i0- —虱吖哫-9-基或-10_基、2 3 — & # 硫吡喃-2-基ί其七」# / ,-—虱本弁 去 土〆口 __ 土、或二苯幷硫吡喃-4 β基。、 田 C ] -6) fe基時之有用實例爲甲基、 基、異丙基、丁基及異丁基。 基、丙 田代表(C3 _6)烯基時之有用實例爲烯丙基。 田R代表(C3 _ f))炔基時之有用實例爲丙炔基。 ’ 當R3代表視情況取代之芳族基時,其較好代表 或經1或2個選自鹵素、(c Α 3 /ρ 、Γ卜 耳代 一 u ^ (Li'4)k基及(ci-4)烷氧基之取 基取代之2-萘基或苯基。 代 經濟部中央標隼局員工消費合作社印製 當R。代表視情況取代之芳族基時之有用實例爲2•关某 苯基、氟苯基、3-氟笨基、4-氟苯基、3,4-二氟笨^、 五氣苯,基、2 -氟爷基、3 _氣苯基、扣氣苯基、3 ^ 土、、2,5 -二氯笨基、2 _溴苯-基一、3 _溴苯基、4 _溴笨基、) 曱基笨基、3_甲基苯基、4 -甲基苯基、2 -甲氧笨基、3_甲 氧笨基、4 -曱氧苯基、3-三氟曱基苯塞及仁三氟甲基笨, -11 - 本紙張尺度適用中國國家標準(CNS ) A4規枱(210X297公釐) 505623 五 B7 經濟部中央標準局員工消费合作社印製
、發明説明(基。 時=:取=)燒基、(C“)晞基或(c“)块基 ,p . — ' 1馬可馬未取代或在苯基上經1或2個自素、二4)=及(Cl-4)烷氧基取代之苯基(u烷基及聯苯 卷(C 1 _ 4 )烷基,例如芊其 ^ 7甘 芙 甘.1基、2_奉乙基、2_苯丙基及2-硫苯 ""”他貫例爲(C3-6)環烷基(Cy)烷基如環丙基甲基。 當以表視情況取代之雜芳族基時之有用實例爲2“密咬基0 ^之特別有用實例爲氫及(〇ι·6μ先基如甲基或乙基。 之特別有用實例爲氫及(Ci6)烷基如甲基或乙基、 之特別有用實例爲(〇卜6)烷基如甲基。 R. <更特別有用貫例爲氫、(Ci 6)烷醯基如乙醯基、苯 甲s&基、(Cu)烷基如甲基及(C3-6)環烷基(Cu)烷基如 環丙基甲基。 . ’ 政V之更特別有用實例爲氫、((:1·6)烷基如甲基及(Cry % k基(C丨·4) j:完基如環丙基甲基。 R6之特別有用實例爲氫、甲基及乙基。 R(a足特別有用實例爲氫、甲基及乙基。 R 、Rs、R9及R10之更特別有用實例爲氫、(U烷基 如甲基,及視情%斧代之芳族基如苯基。 依據本發明之特別類化合物爲其中 (a)R 代表氟、x〇r。、、sc^H CN或P〇3r26且r2代表氫:或 四唑-5 -基 (請先閲讀背面之注意事項再填寫本頁) •f
、1T -12- 表紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公楚 505623 經濟部中央標準局員工消費合作社印製 A7 _________ B-7 Τϋ —— -- 五、發明説明() (b) R1及R2各代表氟:或 (c) R1及R2合而代表二〇、或= cr8R9 :或 (d) R1及R2代表胺基及另一個代表羧基之化合物。 R1及R2特別有用者爲: U)Ri 代表氟、XOR3、xnr4r5、s〇3H、四唑 ^基、 CN〇〇3H2 : X代表化學鍵、CO或CH2 ,· R3代表氫原子 或(C!-6)烷基:爲未取代或個各選自_素、(Cl 4) 烷基及(C^4)烷氧基之取代基取代之苯基一:爲未取代或^ 苯環上—經1或2個選自_素、(Ci4m基及(c")貌氧基取 代之苯基(Ci·4)烷基或聯苯基(Ci·4)烷基:R4代表氫、 (Cl-6)烷醯基、苯甲醯基、(q-6)環烷基(Cl_4)烷基或 (Cl-6)烷基:及^代表氫、(C3-6)環烷基(Cm)烷基或 (C 1 · 6 ) fe基:及R 2代表氫;或 (b) R1及R2各代表氟:或 (c) r1&r2代表=〇、=N〇H或= CR8r9,其中r8&r9各獨 立代表氫原子、(c^6)烷基或可爲未取代或經個選自 自素、(Cm),基及(Ci4m氧基之取代基取代之苯基: 或 (㈨…及112之一代表胺基及另一個代表羧基:或 (C)Rl 代表 I 、 CH2C〇〇R3a 、 CH2p〇j26a 、 nhconhra 或 N/HS〇2R3c: R3a代表氫或(ci6)院基:R3b 代表(Cm)燒基:Rh代表(c「6m基:r2代表氫:及R6a 各獨立代表氫或(C丨_6)烷基:或 ⑴R及R合而代表sCHCOOH、二CHP〇3H2 、 •13- 本纸張尺度適用中國國豕標準(CNS ) A4規格(21 Ο χ 297公參)"" ~ — --------衣-- (請先閱請背面之注意事項再填寫本頁} -、11 經濟部中央標準局員工消費合作社印製 川 5623 kl '-〜--_____ B*7 ___ 五、發明説明(11 ) — = CHP〇3(C2H5)2 或= CHCN。 此基中,R1及R2特別有用者爲: U)Ri代表氟:x〇R3 : XNR4R5 : s〇3H : ® 唑-5-基: CN或p〇3H2 : X代表化學鍵、cH2或CO : R3代表氫原 子;(C!·6)烷基:爲未取代或經1或2個各選自齒素、(Cl· 4) fe基及(C〗_4 )烷氧基之取代基取代之苯基··爲未取代或 在笨環上經1或2個選自鹵素、(Cl_4)烷基^(Cm)烷氧基 之取代基取代之苯基(Ci4)烷基或聯苯基(c—14)烷基;R4 代表氫、(Cu)烷醯基或(Ci 6)烷基:及!^代表氫或(Ci、) 烷基:及R2代表氫:或 · (b ) R及R2各代表氟:或 (c)R及R合而代表二〇、=n〇h或= CR8R9,其中R8及R9 各獨互代表氫原子、(C丨_ 6)燒„基或爲未取代或經1或2個各 ^自_ I、( C 1 -4) fe基及(C 1 ·4 )坑氧基之取代基取代之苯 基;或 (d ) R 1及R2之一代表胺基及另一個代表羧基。 較好R 1代表氟、羥基、p 〇 3 Η2、甲氧基、胺基、疊氮 基、乙酸胺基、笨甲醯胺基、甲磺醯胺基、甲胺羰胺基、 Ν,Ν -二環丙基甲基、羧基、氰基或曱醯胺基及R2代表氫, 或 R 與 R2 合而代表二 〇、=n〇h、二 CHC〇2H、=CH2、 = CHP(^(C2H5)y=CHP〇3H2 或二 CHCN。 式I化合物實例包含: ·一 2 -胺基-4 -羥基雙環[3 . 1 . 0 ]己烷-2,6 -二羧酸: 2 -胺基-4 -氟雙環[3 · 1 · 0 ]己烷-2,6 -二無酸: , -14- 本適财國 (CNSTT^ 21Gx^T^rp~--- (請先閱讀背面之注意事項再填寫本頁) 4
'IT 12505623 Α7 經濟部中央標準局員工消f合作社印製 五、發明説明() 2 -胺基-4,4 -二氟雙環[3 . 1 · 0 ]己烷_ 2,6 -二羧酸: 2 -胺基-4 -羧基雙環[3 . 1 . 0 ]己烷-2,6 -二羧酸: 2,4 -二胺基雙環[3 . 1 . 0 ]己烷-2,6 -二羧酸: 2 -胺基-4 -胺曱基雙環[3 . 1 . 0 ]己烷-2,6 -二羧酸: 2 -胺基-4 -乙醯胺甲基雙環[3 . 1 . 0 ]己烷-2,6 -二羧酸: 2 -胺基-4 -氧代雙環[3 . 1.0 ]己烷-2,6 -二羧酸: 2 -胺基-4 -羥亞胺雙環[3 · 1 · 0 ]己烷-2,6二二羧酸: 2 -胺基-4 -亞磷羧基雙環[3 . 1 . 0 ]己烷-2,6 -二羧酸: 2 -胺基-4 -甲氧雙環[3.2 . 1 ]己烷-2,6 -二羧酸: 2 -胺基-4 -疊氮雙環[3 · 2 · 1 ]己燒-2,6 -二複酸: 2 -胺基-4 -苯甲醯胺基雙環[3 · 2 . 1 ]己烷-2,6 -二羧酸L 2 -胺基-4 -甲磺醯胺基雙環[3.2 · 1 ]己烷-2,6 -二羧酸: 2 -胺基-4 -曱胺羰胺基雙環[3.2 . 1 ]己烷-2,6 -二羧酸: 2 -胺基- 4-(N,N -二環丙甲基)胺基雙環[3 ·2. 1 ]己终-2,6-二羧酸: 2 -胺基-4 -羧亞曱基雙環[3 . 2 . 1 ]己烷-2,6 -二羧酸: 2 _胺基-4 -亞甲基雙環[3.2 . 1 ]己烷-2,6 -二羧酸: 2 -胺基-4 -二乙基亞磷羧亞曱基雙環[3 . 2 . 1 ]己烷-2,6 -二 羧酸: 2 -胺基-4 -亞磷羧亞甲基雙環[3 . 2 . 1 ]己烷-2,6 -二羧酸: 2-胺,基-4-氰舍甲基雙環[3 ·2. 1]己烷-2,6-二羧酸: ί 2 -胺基-4 -氰基雙環[3 . 2 · 1·]已烷-2,6 -二羧酸:及 2 -胺基-4 -甲醯胺雙環[3 . 2 . 1 ]己烷-2,6 -二羧酸。 特佳之式I化合物爲: -15- (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規枱(210X29*7公釐) 505623 A7 五、 發明説明(
1T β*7 經濟部中央標準局員工消费合作社印製 (1 S ' 2 S ' ) R ' 6 R * ) - 2 -胺基_ 4 -氧代雙環[3」〇 ]己燒_ 2,6 -二複酸: [〇 . 1 . 0 ]己 fe - 2,6 -二#蔓酸; (15*,25*,5!1*,611*)-2_胺基_4_[順]_羥亞胺雙環 [J · 1 · 0 ]己- 2,6 -二 酸; (18'211'45*,58*,68*)-2-胺基-4-辱1雙環[3.1.〇]己 境-2,6 -二竣酸: (18'28'511'68*)-2-胺基-4-Z-羧亞曱基雙環 (lS’JS ‘,5R'6S*)-2 -胺基-4_ 亞甲基雙環[31〇]己 烷-2,6 -二複酸。 該等化合物爲特別高效力之代謝營養穀氨酸受體調節劑。 本發明包含式I化合物之醫藥可接受性鹽。該等鹽可與分 子之酸性或鹼性部份有關聯地存在且可以酸加成鹽了二 級、二級、三級或四級銨鹽、鹼金屬鹽或鹼土金屬鹽存 在。迥常fe加成鹽之製備係使酸與式!化合物反應。鹼金 及鹼土金屬鹽之製備通常係使所需金屬鹽之氫氧化盥 化合物反應。 上 人式1 慣用以形成此種鹽之酸包含無機酸如鹽酸、氫溴酸、— 碘酸 '硫酸及噚以及有機鹽如對-甲苯磺酸、* = 氫 '、 〒^酸、莖 S文、對-溴笨績酸、碳酸、琥为酸、檸樣酽、# ^ 又 本甲酸及r 酸,及相關無機及有機酸。因此此種醫銥 • G枝為木可接雙鹽包本石六 鉍鹽、焦硫酸鹽、硫酸氫鹽、亞硫酸鹽〈 —η' 他敗氣鹽、瑪 -16- 本纸張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) (請先閱讀背面之注意事項再填寫本頁) .籲衣 訂 505623 經濟部中央標準局員工消費合作社印製 A7 B*7 — -五、發明説明() 酸鹽、按鹽、瑪酸單氫鹽、嶙酸二氫鹽、偏磷酸鹽、焦$粦 酸鹽、氯化物、溴化物、破化物、乙酸鹽、丙酸鹽、癸酸 鹽、辛酸鹽、丙烯酸鹽、曱酸鹽、異丁酸鹽、己酸鹽、庚 酸鹽、丙块酸鹽、草酸鹽、丙二酸鹽、破ίό酸鹽、辛二酸 鹽、癸二酸鹽、富馬酸鹽、馬尿酸鹽、丁決-1,4 -二酸鹽、 己烷-1,6 -二酸鹽、苯甲酸鹽、氯苯甲酸鹽、曱基苯甲酸 鹽、二硝基苯甲酸鹽、羥基苯甲酸鹽、甲_氧基苯曱酸鹽、 酞酸鹽、磺酸鹽、二甲苯磺酸鹽、苯基乙酸鹽、苯基丙酸 鹽、苯基丁酸鹽、檸檬酸鹽、乳酸鹽、a -羥基丁酸鹽、乙 醇酸鹽··蘋果酸鹽、酒石酸鹽-、甲磺酸鹽、丙磺酸鹽、茬- 1 -磺酸鹽、茬-2 -磺酸鹽、扁桃酸鹽、鎂鹽、四甲銨鹽、 鉀鹽、三甲銨鹽、鈉鹽、甲銨鹽、鈣鹽等鹽類。 式I化合物之醫藥可接受性易代謝酯及醯胺爲可在體内水 解而提供該式I化合物及醫藥可接受性醇或胺之式I化合物 / 之酯或醯胺衍生物。易代謝酯之實例包含與(C i _6)烷醇形 成之酯,其中烷醇部份可視情況經(C i _ 8 )烷氧基取代,例 如甲醇、乙醇_、丙醇及曱氧乙醇。易代謝之醯胺實例包含 與胺如甲胺形成之_胺。 依據另一目的,本發明提供一種製備式I化合物之方法, 包括: (a )使下式化倉,物或其鹽水解: ' r (請先閱讀背面之注意事項再填寫本頁) -17- 本纸張尺度適用中國國家標準(CNS ) A4規格(210X 297公t ) 五、 發明説明( 15 kl B7
u R
II 其中R代表氫原子或醯基及R12代表羧基或酯化羧基: (b)使下式化合物或其鹽水解:
R
III (請先閲誇背面之注意事項再填寫本頁)
、1T 經濟部中央標準局員工消f合作社印製 其中R代表羧基或酯化羧基,及Rl4及Rl5各獨立代表氫 原子、(C2_6)境醯基、(Ci 4)烷基、、(C3 4)烯基或苯基 (Cl-4)坑基其-中苯基,爲未取代或經_素^^)烷基或(cU4) fe氧基取代:或 (C )使下式化合物或其鹽脱保護:
K
c〇 p17 -18 - 本纸張尺度適用中國國家榡準(CNS ) A4規栳(210X 297公釐) ^5623 經濟部中央標準局負工消费合作社印製 A7 _ B7 16 ~ — -- 九、發明説明() 其中R 1 8代表氫原子或氮保護基及R 1 6及R 1 7各獨立代表氫 原子或叛基保護基: 隨後,若需要及/或需要: (i)溶解式I化合物: (i i)使式I化合物轉化成其非毒性易代謝酯或醯胺:及/ 或 (1 i i)使式I化合物或其非毒性易代謝酯或醯胺轉化成其醫 藥可接受性鹽。 _ 羧酸及胺基之保護反應通常述於McOmie之有機化護 1,Plenum出版社(紐約,1973 )及Greene及Wuts之有機合 處-#諼基’第二版,John Wiley & Sons出版(紐約, 1 99 1 )。複基保護基實例包含烷基如甲基、乙基、第三丁 基及第三戊基··芳烷基如芊基、4 -硝芊基、4 -甲氧苄基、 3,4 -二甲氧苄基、2,4 -二甲氧芊基、2,4,6 -三甲氧芊基Λ / 2,4,6 -三甲基芊基、二苯甲基及三苯曱基:矽烷基如三曱 基石夕也基及第三丁基二甲基石夕院基:及晞丙基如晞丙基及 1 -(三甲基矽崞甲基)丙-丨_烯_ 3 -基。胺保護基實例包含醯 基如式RaC〇之基,其中Ra代表(Cl·6)烷基、((:31〇)環烷 基、苯基(C丨_) 基、苯基、(C丨-6)境氧基如第三丁氧 基、苯基(C ! _ 6 )烷氧基或(C 3 · i 0 )環烷氧基,其中苯基可視 ’!>]九、纟气1或2個务’選自胺基、喪基、硝基.、齒素、(c〗6) 'j:完 基、(C ! ·6 ) 氧基、竣基、·( _ 6)坑氧羰基、胺甲醯基、 (C ! _6)烷醯胺基、(c】_ 6)烷磺醯胺基、苯磺醯胺基、甲苯 績醯胺基及(C ! · 6)氟:ί完基。 、 -19- 本纸張尺度適用中國國家標準(CNS ) Α4規格(210X 297公茇) --------1ml衣— (請先閱讀背面之注意事項再填寫本頁)
、1T 505623 五 、發明説明( ΤΓ A7 B? 經矿部中央標準局員工消費合作社印裂 n11較有用者爲氫、(C2_6m醯基如乙醯基及第三丁氧幾 基。 R12及R1,代表酯化幾基時較有用者爲(Ci6)燒氧幾基如 乙氧羰基。 R14及R15較有用者各爲氫或芊基。 R16及R17較有用者爲曱基及乙基。 R18較有用者爲第三丁氧羰基。 式Π化合物係在酸如鹽酸或硫酸 物例如氫氧化鉀存在下便利地水解 水中在自50至200。(:範圍之溫度進行 、式III化合物係在驗如鹼金屬氫氧化物例如氫氧化U内 2鉀、,或鹼土金屬氫氧化物如氫氧化鎖存在下便利地水 解。通:£反應介質包含水。溫度宜在5〇至15〇。〇之範圍。 式iV化合物可藉習知方法脱保護。因此,嶋保護基 可精水解移除。水解可在鹼例如鹼金屬氫氧化物如氫氧ς 鋰、鈉或鉀或鹼土金屬氫氧化物如氫氧化鋇存在下,使弋 IV化合物加熱而進行。此水解宜在自1〇至3〇〇1之溫度^ 圍進什。芳烷羧基保護基可便利地藉氫化反應移除。气;: 反應宜藉ί吏式IV化合物與氫在VIII族金屬㈣例如绝觸媒 如鈀/碳存在下反應而進行。此反應之適宜溶劑包含醇如 乙醇。,反應宜存自0至丨00Τ:之溫度範圍進行。酿基7“ 保護基亦便利地藉水解移除·,W如如移除烷羧基保確義户= 述者第三丁氧羰基便利地使用無水氯化氫於溶劑如 S旨中移除。 ‘ 或驗如驗金屬氫氧化 水解宜在含水溶劑如 (請先閱讀背面之注意事項再填寫本頁) .噸. 、1Τ I# -20- 本纸張尺度適用中國國家標準(〇~5)八4規格(210父297公犮) 505623 Μ Β-1 五、發明説明 18 式11化合物之製備可籍使式V化合物:
rj R
K
V 與鹼金屬氰化物如氰化|2、# t 一 應。亦發現可有利地在超音波:二Z化銨如氣化i 鹼金屬氰化物在適宜稀㈣乙广因此自化銨' 氧化-混合。接著混合二:ίΓ她 合物並再照射混合物。“一,隨後添加式-V彳 料映t體異構物胺基猜之.所得混合物在適宜驗例如月 二二 胺存在下及在適宜溶劑如m存在下》 =劍反應,而得非對映立體異構之畴基腈之混合物 :㈣對映立體異㈣可便利地以'例如層析法自混合4 中分離。 ’ 匕合物可於含水醇如含水乙醇中,使式V化竭 經濟部中央標準局員工消費合作社印製 驗至屬泉化物如I化押、#斗、力π山 < >1氰化鋰鈉或鉀及碳酸銨反應而製備。4 怒且在自J5主150 c之溫度範圍進行。若需要,接著★ 11丄化貪物可使,例如式尺^丨或…〜及/或^⑴ R )Br之適宜化合物烷化或醯作。 或者,式ίΠ化合物可由類似於本技藝悉知之方法之程/ 由F式化合物製備: 、 -21 - 本纸張尺度適用中國國家標準(CNS )A4規格(210x 297公楚) 505623
五、發明説明( Η 0
RJ
VI 請 先 閲 經濟部中央標準局員工消費合作社印製 因而,例如式中R 1代矣〜 — 物可藉式VI化合物盥、Γ 基及R2代表氫之式111化合 式中R I代4”逆’、刎如獨氫化鈉反應而製備。 ^ Ιπ^ν碘二子口 中5代表離去原子或基,如氯:溴或 、.、S 5…甲本磺醒.氧基)在鹼如氫化鈉或第三丁醇鉀存 下反愿而製備。此反應宜在自〇至1G(TC之溫度範圍内進 仃。通:ϋ溶劑包含醯胺類如二甲基甲酿胺、亞諷類如二甲 基亞砜及醚m如四氫呋喃。·或者、,,此化合物可利用 Mitsunobu化學法製備,如述於BuU以⑽s〇c】叩心,4〇, 2380, 1967 。 式中R 1及R2均代表氟之式II、111或I V化合物之製備,係 使式中R1及R2倉丨而代表=〇之式π、ΙΠ或丨v對應化合物分 別與氟化劑如三氟化二乙胺-奉〜硫或三氟化二甲胺基硫反應 而得,係依據 J·〇rg Chem·,50, 1599, 1985 及 Tet. Lett., 34 (3 1),4917, 1993所述方法進行、此反應宜在溶劑如二氯 -22- 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X297公趁) 背 面 注 意 事 項 再 填 寫 本 頁 訂 川 5623 第87107483號專利申請案 中文說明書修正頁(91年3月)
發明説明 ¥ 甲烷或四氫呋喃中,在自〇至50。(:之溫度範圍内進行。或 者,氟化劑為在三氟乙酸中之氟化氫及與鋅粉之
Chem· Soc· Perk· Trans· 1,3, 335, 1993 )。或者,其中與 R2合而代表=〇之式Π、ΠΙ或IV化合物可藉與 HzSCHAHdH反應再與Βίν乙酸錯合物反應而轉化^二 硫環戊烷(J. Org. Chem. 51,3508,1986)。 式中R1及R2合而代表=NOR6之式Π、ΠΙ*ιν化合物之製 備可藉由式II、III或IV對應化合物與式H2N〇R6之羥胺或 其酸加成鹽,在鹼如氫氧化鈉、乙酸鈉或三乙胺存在下反 應。此反應宜在自0至5 0 c溫度範圍内,在極性溶劑如乙 醇,含水乙醇或二甲基亞砜中進行。 式中R1代表胺基及R2代表氫之式Π、ΠΙ或IV化合物可藉 使式中R1及R2合而代表=Ν0Η之式II、III或IV對應化合物 還原而製備。適宜還原劑為在貴金屬觸媒如鈀/碳或阮尼 鎳、氫化鋰鋁、硼烷或鋅與乙酸存在下之氫。或者,其可 藉使式中R1代表疊氮基及R2代表氫之式Π、Π][或IV化合物 還原而製備。還原宜使用三苯膦在含水四氫呋喃存在下, 在自0至100 °c之溫度範圍進行。 式中R1代表NH2之式II、III或IV化合物可經烷化或醯化 而得其中R1代表NR4R5之對應式II、III或IV化合物,例如 藉使用式R4Z2或R5z3(其中Z2及Z3代表離去原子或基如氯 原子或對-甲苯磺醯氧基)之化合物烷化;使用醛或酮及還 原劑如氫硼氰化鈉之還原性烷化反應,或使用醯基鹵或酸 酐之醯化反應。 -23- 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 505623 A7 B-7 五、發明説明() 式中R1代表NHC〇NHR3b之式II、III或I V化合物之製 備’可使其中R 1代表胺基之式Z 、n Z或I V對應化合物與式 ' R - Ν - C - 0之異氰酸g旨反應。便利之溶劑包含二氯曱燒。 式中R1代表NHS02R3c之式II、III或IV化合物之製備, 可使式中R 1代表胺基之式Z、π丨或I V對應化合物與式 R3es〇2Z4續SS自(其中Ζ4爲例如氯或溴)反應。此反應宜在 驗如三乙胺存在下及於溶劑如二氯甲烷中進行。 式中R 1代表氟及R2代表氫之式][][、π}或Z V化合物之製 備,可使式中R1代表羥基及R2代表氫之式π、^丨丨或…對 應化合物與三氟化二乙胺基硫或三氟化二曱胺基硫依據Tet.
Assym·,4(2),161,1994之方法反應。此反應宜在自2_〇至 5 0 C之溫度範圍,於溶劑如二氯甲烷、甲苯或四氫呋喃存 在下進行:·或者,醇可在鹼如三乙胺存在下依Syn.,3, 273, 1994所述方法與氟化鈽及四丁銨反應。另一種便利氟化劑 爲聚_(4-乙晞基吡啶鑌)聚氟化氫(Syn· Lett., 5, 267, 1990)。 , , 經濟部中央標率局員工消费合作社印製 --------^0界-- (請先閱讀背面之注意事項再填寫本頁 式中R1代奉CN或疊氮基之式η·、Ιπ或…化合物之製 7,可使式中111代表羥基之式Π、Π!或…對應化合物與烴 績醯Fl如對.甲苯伽氯或Μ醢氣例如在心作爲反應溶 劑中反應’再與氰化物鹽如氰化神,或與叠氮鹽如疊氮化 物例如在二曱辱亞砜作爲反應溶劑中反應。 式中R代农沒基足式:[丨、π μ或丨V化合物可藉使對應之腈 水解而製備。所得|基化合物若需要接著可藉習知方法醋 化或轉化成式C〇NR4R5之醯胺。' ‘ 曰 -24- 本纸浪尺度適用中國國家標準(CNS)A4規格(210χ29フ公楚) 505623
第87107483號專利_請案 A7 B7 中文說明書修正頁(91年3月) 五、發明説明(22 ) 式中R1代表CH2NR4R5之式II、III或IV化合物之製備, 可藉例如在鈀/碳或阮尼鎳存在下之氫化反應使對應之腈 還原,接著若需要如上述般烷化、還原性烷化或醯化。 式中R1代表四唑基之式III或IV化合物之製備,可使式中 R1代表CN之式III或IV對應化合物與疊氮化物如四丁基三 疊氮化物反應而得。 式VI化合物之製備,可使下式化合物:
與氧化劑例如瓊斯(Jones)試劑(Cr〇3,H2S〇〇反應而得 式V Π化合物之製備,可使下式化合物:
與鹼金屬氰化物如氰化鉀及碳酸銨反疯, 式R B r或R B r之化合物予以境化或酶化
用式R 4Βγ或R 接著若需要使 -25- 505623 kl m 五、發明説明( 式中R!及R2合而代表二CR8p9 ' 4 制備} R又式II、III或IV化合物之 1備,可由式中R〗&R2人石 σ 代表Γ〇之式11、111或I V對靡 :5物以威提(wmlg)反應製備,例如與 : 齒化物反應所形成之式ph3p=CR8R9化合物反鹿。…基 式中R1及y合而代表=CHC00R3b、=aip〇 二CN之式11、111或1V化合物之製備,可由威瓦I艾蒙 (°rth_Em_s).反應由式中R1及y合而代表=0之式 II、ITI或I v對應化合物製備 — 例如與二烷基亞磷羧基乙酸 -…驗金屬鹽·,如二乙基·亞嶙幾基 之 亞甲基二膦酸四烷酯如亞甲: , 内皿 一r t 肀基一駟鉍四烷酯或氰甲基膦酸 一烷g日之鹼金屬鹽如氰甲基鱗 P G S曰又鈉鹽反應。此反 角=在:水溶劑如無水甲笨中進行。R6a所示找基可藉水 角午例如使用酸如三氟乙酸或鹽駿而移除。 化irr2合而代表(CH山p〇3R、之式!卜⑴或iv 下備’可藉例如在νπι族金屬觸媒純/'碳存在 =1化反應〈還原反應由式中R1及!e合而代表 = chP〇3R、之式„、⑴或IV對應化合物製備。 式VIII化合物之製備,可使下式之化合物, 經濟部中央標準局員工消費合作社印製
Ή ο A7 B-7 五、發明説明(24 ) ' 與硫醇如N -乙醯基_ l -半胱氨酸、鹼如硼酸鈉及二芳基 二晒化物如二苯基二硒化物反應而得。· • 式1X化合物之製備,可使下式化合物: .Η
Μ過氧化物如弟二丁基過氧化風反·應而得。 式中R 1代表Ρ〇3 R/且各R6代表(C〗_6)烷基之式v化合物 之製備可在酚存在下,使式X化合物與三烷基亞磷酸酯如 二乙基亞轉酸g旨反應。 式中R1代表SO; Η及R2代表氫之式III、IV或v化合物之 製備,可使用如過氧化氫及硫酸(Chem. Pharm. Buli. 197 1 i9,2 2 22 )、硝酸(J· 〇i’g. Chem.,1961,26,82)或過氧化礼 及乙酸(Helv. Chem. Acta. 1986, 349,322),使式中 代表 SH及R2代表氫之式in、IV或V對應化合物氧化。 經濟部中央標隼局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 式中R1代表SH之式III、IV或V化合物之製備,可使式 中R1代表苄硫基之式I π、I v或v對應化合物於液態氨中與 鈉反應而脱羊奉化(Angew. Chem. 196.7,6, 698 ; 〇rg s》, 1986, 65, 215)〇 -- ' 式中R 1代表苄硫基之式V化合物之製備,可在驗如二乙 胺存在下使式X化合物與苯硫醇反應。' -21 - 本紙張尺度適用中國國家標举(CNS ) A4規格(210、乂 297公釐) 五 '發明説明( 25 A7 B-7 + :明瞭式vm化合物相當於式中Ri代表羥基及r2代表氫 ’ V化'物。其他式V化合物可由式V 111化合物藉保護 :基再依類似於本技藝悉知程序使所得經保護化合物轉化 成式V化合物而製備。 式x化合物之製備,可使式XI化合物:
(請先閲請背面之注意事項再填寫本頁) 經濟、邓中央標準局員工消費合作社印製 钍6胺存在下與破二甲基n完反應而得梦燒基晞醇 醚,再使該矽烷基晞醇醚與乙.酸鈀反應。或者,可使式幻 化合物與碳酸稀丙醋甲醋在乙酸鈀(⑴存在下反應而製 備。反應宜在無水乙腈中進行。 ’ 式X I化合物爲已知且可使八環戊晞、_ b酮與羧基保護之 (二甲基亞硫烷基)乙酸酯反應而製備、。適於此反應之=劑 包含芳族烴類如甲基。可藉層析法單離所需之非對映立體 產物。 式I V化合物可藉使式〖化合物爲保護而製備,例如在脱水 劑如亞硫醯氣令在下與醇如乙醇反應以使羧基保護,並使 所得酯如BokO反應而使胺基|護。式中R1&R2合而代表 〇(式I v化合物可藉類似於本技藝悉知方法之程序轉化 成對應之式I V化合物。 * -28- 本紙張尺度適用中國國家標準(CNS ),A4規格(210X297公# )
iT 505623 A7 &7 五 、發明説明( 26 式I化合物可使用習知方法解析,例如與、 形成結晶鹽。或者,使用光學活性起始::性酸或鹼 之式I化合物。 衣備王光學純態 相信式II、III及IV化合物爲新穎且爲本發明另— 依本發明投藥之化合物特定劑量當然依特定戸户目的。 而決定,包含投與之化合物,途藥途秤,、Λ二竟特足例 ^ >口療之特定修# 及類似考量。化合物可藉各種路徑投藥,勹人 ·、 ^ 〜匕3 口月艮、.直 軔、經皮、皮下、靜脈内、肌肉内或I由?々斤上 J U劣异内路徑投藥。或者 化合物可藉連續滴注而投藥。典型曰劑 里补含約〇·〇1毫克 /公斤至約100毫克/公斤之本發明化合物。較好,曰, 量約0.05毫克/公斤至約50毫克/公斤,更好約〇」毫克> 公斤至約25毫克/公斤。 各種生理功能顯示可藉興奮·性胺基酸傳遞之過量或不適 靣刺激作用而影響。本發明式I化合物相信具有處理哺乳類 有此病況之各種神經學障礙,包含急性神經學障礙如心臟 旁通手術及移植後之腦缺陷.,中風、腦絕血、脊髓損傷、 頭損傷、出生-前後氧不足、心動停止及低血糖神經損傷。 式I化合物相信具有處理各種慢性神經學障礙,如阿兹海默 氏疾病、f 丁頓氏舞蹈病、肌萎縮性側索硬化、AIDS、謗 發之癡呆、眼損傷及視網膜病,認知力障礙及原發性及藥 物誘發,之帕金泰/氏症。本發明亦提供治療該等障礙之方 (; 法’包括對需此治療之病患投輿有效量之式I化合物或其醫 藥可接受性易代謝酯或醯胺或其醫藥可接受性鹽。 本發明式I化合物亦相信具有可治療哺乳‘類因穀氨酸功能 -29- 本纸張尺度適用中國國家標準(CNS ) A4規格(210X29*7公釐) (請先閱讀背面之注意事項再填寫本頁) 、-口 經濟部中央標準局員工消費合作社印製 505623 A7 27 經濟部中央標準局員工消費合作社印製 五、發明説明( 不足之各種其他神經學障礙,包本 .R ^ 、 匕。肌肉經攣、搐搦、偏頭 ,水禁、戒除煙瘾、精神病(如精神分裂症卜阿片刀、 耐力及戒除、焦慮、呕吐、腦浮腫、慢性疼痛、及遲^ 運動困難。式1化合物亦可作爲抗抑㈣及止痛劑。因此本 發明耶提供一種治療該等障礙之方法,包括對需此治療之 投與枝量之式!化合物或其醫藥可接受性易代謝醋或 6&胺或其醫藥可接受性鹽。 化合物調節代謝營養性穀氨酸受體功能:能力可藉檢視 其於細胞中影響cAMP產生(mGluR 2,3,4,6,7或8)或 π I肌知水解(mGluI^或5 )而表現該等個別人類代謝營養 性穀氨酸受體(mGluR)亞型加以證明。(D D Sch〇epp等人
Neuropharmacol.,1996, 35, 1661-1672 及 1997, 36, 1-1 1 )。 本發明化合物較好經調配後投藥。因此,本發明另一目 的係有關一種醫藥調配物,包括式I化合物及醫藥可接受性 $體、稀釋劑或賦形劑。本醫藥調配物可使用悉知且易獲 侍 < 成分以已知程序製備。製造本發明組合物中,活性成 分m常與載體-混合,或以載體稀釋或包封於載體中,且可 主%、囊、樂囊、紙或於其他容器中。當載體作爲稀釋劑 寺其可爲作爲活性成分之載劑、賦形劑或介質之固體、 半固體或液體。此組合物可呈錠劑、丸劑、粉劑、錠片、 藥囊 '烏囊劑)巧酏劑、懸浮液、乳液 > 溶液、糖漿、氣 "谷L 叙賞、其含有例如達·ι 重量%之活性化合物,軟及 硬明膠勝囊、栓劑、無菌可注射溶液及無菌包裝粉劑。 適S载體、賦形劑及稀釋劑之某些實#包含乳糖、葡萄, - 30- )Α4規枋(210x 297公釐) (請先閲後背面之注意事項再填寫本I)
505623 A7 — B-7 ~ " 28 ' -----^五、發明説明() 糖、蔗糖、山梨糖醇、甘露糖醇、澱粉、阿拉伯膠、磷酸 鈣、藻朊酸鹽、西黃葦膠、明膠、矽酸鈣、微晶纖維素、 聚乙烯吡咯烷酮、纖維素、水糖漿、曱基纖維素、羥基苯 甲酸甲酯及丙酯、滑石、硬脂酸鎂及礦油。調配物又可包 含潤滑劑、澄潤㈣、乳化劑及懸浮劑、保存劑、甜味劑或 矯味劑。本發明組合物可利用本技藝悉知程序調配成對病 患投藥後可快速、持續或延遲釋出活性成分者。 此組合物較好調配成單位劑型,各劑型含有約5毫克至約 500毫克,更好約2 5毫克至約300毫克活性成分。,,單位劑 型表示適合作爲人類或其他哺乳類之單位劑量之物理分隔 單位,各單位含有經計算以產生所需療效之預定量活性物 質,以及適宜之醫藥载體、稀釋劑或賦形劑。下列調配例 僅用以説明而不欲限制本發明之範圍。 碉配例1 / 使用下列成分製備硬明膠膠囊·· (請先閱讀背面之注意事項再填寫本頁) .«冬· 訂 經濟部中央標準局員工消費合作社印製 量(毫克/膠囊) 活性成分 一 ^ \ yu X 以夕 / ---- 250 乾澱粉 200 硬脂酸鎂 復 合計 460 毫克 ____ / , « 上述成分經混合並以460毫· t量塡 :入硬明膠膠囊。 調配例2 如下製備各含6 0毫克活性成分之鏡劑*、 -31 - 本纸張尺度適用中國國家標準(CNS ) A4規格(2Ϊ〇Χ297^7 刈5623 A7 B5 五、 發明説明( 活性成分 澱粉 微晶纖維素 聚乙烯巧1:哈燒酉同 羧甲基澱粉鈉 硬脂酸鎂 滑石 合計. 60毫克 45毫克 35毫克 4毫克 4.5毫克 〇.5毫克 _ 1毫克 (請先閱讀背面之注意事項再填寫本頁) 衣 濟 部t 央 標 準 局 消 合 作 社 印 成刀澱切及纖維素通過美國4 5號網目網篩並充分 混合。聚乙晞吡咯烷酮之溶液與所得粉末混合,再通過美 國14號網目網篩。製得之顆粒在5代乾燥並通過美國18 I ’同目...罔篩。接著使叛甲基殿粉鈉、硬脂酸鎂及滑石先通 過美國6 0唬網目網篩後,再添加至顆粒中,混合後製錠機 上壓縮產生各重1 5 〇毫克之鍵劑。 下列貫例進一步説明本發明化合物及其合成方法。 於下列中使J下列縮寫:EtOAc,乙酸乙酯:THF,四 氫吱喃:Boc,第三丁氧羰基:B〇C2〇,第三丁氧羧酸 酐:Et〇H,乙醇:Et2〇,乙醚:DBU,1,8 -二吖雙環 [5.4 · 0]十一碳-7 -烯:及FDMS,場吸收質譜。 , '、製備例1 臭化咬乙氧曱基二曱基疏鹽·一 溴乙酸乙酯( 265克)及二甲基硫化物(1 14克)於丙酮(500 毫升)之溶液在室溫攪拌。3天後,過濾反,應混合物而單離 本纸張尺度適用中國國家標準(CNS ) Λ4規枱(210X 297公犮) 505623 經濟部中央標準局員工消費合作社印製 A7 . ----- B-7 "3〇 ' -————__ 五、發明説明() 目的化合物,熔點88-90 3C。 製備例2 , (1 S *,5 R *,6 S * ) 2 -氧代雙環[3 . 1 · 〇 ]己烷_ 6 ·羧酸乙酯 含溴化碳乙氧甲基二曱基銳鹽(45.5克,198.6毫莫耳)之 甲表(3 5 0毫升)怒;手液以1,8 -二口 丫雙環[5 4 . 〇 ] Ί 石炭-7 _ 埽(30.2克,19 8.4耄莫耳)處理,所得混合物在室溫攪拌, 1小時後’反應混合物以2 -環戊烯-1 _酮(19.57克,238.4.毫 莫耳)處理。再1 8小時後,反應混合物加至LN鹽酸/氯化 鈉溶液中。所得混合物以乙醚萃取。合併之醚萃取液以硫 酸鎂脱水、過濾並眞空濃縮。濟留物使用矽膠層析法,以 1 〇 %乙酸乙酯/己烷至5 0 %乙酸乙酯/己烷線性悌度溶 離,得22.81克(6 8%)目的化合物,熔點3 6 - 3 8 °C。 FDMS ·· M/Z 二 168 (M,+)。 _ 對C9H1203計算分析値:C,64.27; H,7.19。實測値:C, 65.54, H, 7.1 卜 實例1 » 、 (1 S *,2 R *,4 S * , 5 R *,6 R * ) - 2 -胺基-4 -羥基雙環[3 . 1 · 〇 ]己 燒-2,6 -二複酸
1 OH
. -33- 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X297公摄) (請先閱讀背面之注意事項再填寫本頁) .-HI衣. 、17 505623 Μ 五、發明説明() (a ) 2 -氧代雙環[3 . 1 . 0 ]己-3 -烯-6 -羧酸(1 S *,5 R *,6 S * ) 乙酯。於含2 -氧代雙環[3 · 1 . 〇 ]己-6 —羧酸乙酯(3 7克,220 笔莫耳)及三乙胺(67克,660亳莫耳)之Ch2C12( 1升)溶液 中’在0 C下滴加破三曱基矽垸(5 〇克,2 5 0毫莫耳)並攪拌 1小時。反應混合物以E 12〇稀釋,以NH4C 1飽和水溶液洗 “ ’以M g S〇4乾燦並濃縮得石夕'坑基歸醇酸(9 7 %)。於0 C下 在含矽烷基烯醇醚之3 00毫升c H 3 C N溶液中一次添加 Pd(〇Ac)2。所得反應混合物溫至室溫並攪拌隔夜。反應混 合物以EhO稀釋,經矽藻土過濾並使產物吸附至25〇克 Si〇2上。吸附之氧化矽置於氧化矽墊上端,以己烷/ EtO Ac ( 4 ·· 1 )溶離產物且所得粉紅色固體以£ 12 〇分散:得 29.4克(8〇%,I77毫莫耳)白色固體之目的化合物。 m.p. = 7 8 - 8 0 °C,FDMS : Μ + =16ό,對 C9H1()〇3 分析計算 値:C,65.05; H,6.07。實測値:c5 65.34, H, 6.10。 (a 1 ) 2 -氧代雙環[3 . 1 . 0 ]己-3 -烯-6 - #复酸(1 S *,5 R * , 6 S * ) 經濟部中央標苹局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 乙醋之另一種製法。於配置有N 2入口及回流冷凝管之火焰 乾燥過之3頸3升圓底瓶中,添加含製備例2產物(1〇2克, 424党莫耳)之425毫升無水C Η 3 C N溶液、碳酸烯丙酯曱酯 (99克,848 ¾莫耳)及Pd(〇Ac)2(4.6克,20毫莫耳)。所得 反應混合物下降至預熱至7 0 °C之加熱浴中。當内部反應溫 度達40°C時,暴,體劇烈冒出並在反應完成3〇分鐘後停止逸 出。反應混合物以Et〇Ac(2升-)稀釋,經Si〇2(約250克)過 滤並減签濃縮’得8 0克粗產物。自1 〇 % Et〇Ac /己燒中再 結晶’得粗產物,各方面均與步.嗓(a )中所得者相同。 -34 - 本纸張尺度適用中國國家標準(CNS ) A4規桔(210><297公浼) 505623 經濟部中央標準局員工消费合作社印製 五、發明説明( ~3Σ Α7 (b ) 2 -氧代雙% [ 3 . 1 . ο ]己 _ 3 _ 埽氧 _ 6 •羧酸(i s *,3 R *, 乙酯。含步驟(a)產物(1〇」克,6〇 8毫莫 耳)之·THF( 300笔升)落液在下依序以DBU(27 75克, 1 82耄莫耳)及第二丁基過氧化氫處理。所得反應混合物在 〇 C攪拌1小時,以EhO稀釋,並以1N HC1分配。產物以 EhO萃取,以MgSh乾燥,且所得固體以己烷/ Et〇Ac(9 : 1 )分散,得9.83克(8 9。/〇,54毫莫耳)目的化合 物。mp二 Η)2 - 104°C,FDMS : M-+1 = 18-2。對^仏。〇4分 析計算値:C, 59.34; H,5.53,實測値:C, 59·24; H, 5.53。 ’ (02-氧代-4-羥基雙環[3丨〇]己烷_6_羧酸 (1S*,4S*,5R*js*)乙醋。於含N-乙驢基_L_半胱氨酸 (25.64克,157 ci:莫耳)、硼酸鈉· 1〇h2〇(59別克,⑸ 毫莫耳)及二苯基二硒化物(0.δ2克,2 62亳莫耳)之水/ EtOH(l : 1 )( 500毫升)攪拌除氣體懸浮液中,添加,冬步驿 (b)產物之THF( 250毫升)。完成添加後,反應在室溫攪= 隔夜。—反應混合物以Eh〇稀釋並以Η"分配。產物以 EhO萃取,以HbO再以食鹽水洗滌,並以MgS〇4乾燥。產 物以HPLC(己烷/EtOAc)純化,得7 91克(82%,43亳莫 耳)目的化合物。1^二60-62。(:,1^奶:1^、184二= C9H12〇4之分析計算値:c, 58 69; H,6 57,實測値:〔 58.70; H,6.34。 一 ’ (d ) 2,5 1 -螺乙内醯脲_ 4 _羥基雙環[3」〇 ]己烷_ 6 _羧酽 (1S*,2S*,4S*,5R*,6R*)乙醋:於含步驟(c)產物(7久= -35 本纸張尺度適用中國國家標準(CNS ) Α4規枱(210X 297公漦) (請先閲讀背面之注意事項再填寫本頁 -«衣
'1T #
KJ 3 A7 五 經濟部中央標隼局員工消費合作社印製 _ 阴__ 33 —-----~—- 發明説明() ί«τ (請先閱讀背面之注意事項再填寫本頁 克,40.7毫莫耳)之£〖〇八〇/:»20(1:1)(總體積1〇0毫升) 掩掉溶液中,添加NH2C〇2NH4(9.54克,122.2毫莫耳)再 添如KCN(3.97克,61.1毫莫耳)。添加完成後,反應混合 物在4 0 C溫熱隔夜。反應混合物冷卻至室溫,酸.化至 P Η = 3並藉眞空過濾移除所得沉澱物,產生非對映立體異 構物乙内醯脲之1 : 1混合物。自Et〇H (3 X)再結晶,得 0.79克(3· 1毫莫耳,8%)所需非對映立體普構物。mp = 201 - 2〇3°C,FDMS : M、1 二 255,對 · 〇·6Η2〇分 杆計算値:C, 49.85; Η,5.78; Ν, 10.57。實測値:C,49.60, Η, 5.68; Ν,10.38。 一 (e ) ( 1 S * , 2 S *,4 S *,5 R * , 6 R * ) - 2 -胺基-4 -羥基雙.環 [3 . 1 . 0]己烷- 2,6 -二羧酸。含步驟(d)產物(0.35克,1.38 堂莫耳)之1 N N a〇Η ( 1 5毫升)溶液回流加熱隔夜。反應混 合物冷卻至室溫並調整至ρ Η二8。過濾所得固體並丟棄/ 液再以IN Na〇H調整至ρΗ=12並施加至Bio-Rad@ AG1-陰離子交換樹脂(乙酸酯態轉化成氫氧化物態)。產物以 3N乙酸溶離:得0.25克(90%,1.2毫莫耳)目的化合物。 mp = > 275 〇C。FDMS : ΙνΓ+1 二202。對(:8^111购5 · 0.25 Η20 分析計算値·· C, 46.72; Η,5.64; Ν, 6.81。實測値:C, 46.68; Η, 5.72; Ν, 6.59。 , 、、, 實例2
V (1 S*,2S '5R*,6R*)-2-胺-基—-4 -氧代雙環[3 · 1 ·0]己烷-2,6 -二幾酸 -36- 本纸張尺度適用中國國家標準(CNS ) Λ4規枱(210X 297公浼) 34505623 Α7 Β-7 經濟部中央標準局員工消費合作社印製 五、發明説明()
(a )2-(3,-苄基-5,-螺乙内醯胺)-4_羥;^雙環[3· 1.0]己 烷-6 -羧酸(1 S * , 2 S * , 4 S * , 5 R * , 6 R * )乙酯。_於含實例1步 驟(〇產物(14.5克,78.7毫莫耳)之£1〇《[/:92〇(2:1)(總 體積150毫升)之攪拌溶液中添-加NH2C02NH4(18.42克, 236毫莫耳)再添加KCN( 7.68克,118毫莫耳)。添加完成 後,反應混合物在4 0 °C溫2天。反應混合物眞空濃縮,以 Et〇Ac/ IN HC1及食鹽水分配?以EtOAc萃取乙内醯脲之混 合物,以MgS〇4脱水並濃縮。粗乙内醯脲再於D M F ( 5 0毫 升)中復原,再以NaHC〇3( 16.85克,200毫升)之形式於室 溫下攪動,再連續添加_基溴(12.6克,7 3.5毫莫耳)。反 應混合物在1 〇〇 °C加熱隔夜。反應混合物以Et〇Ac稀釋並以 〇.5N HC1分配。乙内醯脲以EtOAc萃取,以H2〇再以食鹽 水洗,以MgS04脱水,並經HPLC(己烷/EtOAc)純化,得 5.14克(19%,14.9毫莫耳)目的化合物。FDMS : M〜344。對 Ci8H9qN9〇5之分析計算値:C,62·78: H,5.85; , "r ~ Ν,8.13。實測値:C,62·97 ;-HT 5.97; Ν,8.06。 (b ) 2 - ( 3、苄基-5 ’ -螺乙内醯腸)-4 -氧代-雙環[3 . 1 . 0 ]己 烷-6 ·羧酸(1 S *,2 S * , 5 R *,6 R * )‘乙酉旨。、含步驟(a)產物, -37- 本纸張尺度適用中標準(CNS ) A4規格(2丨0'乂 297公趁1 — (請先閲讀背面之注意事項再填寫本頁)
、1T 505623 A7 35 -------------- 五、發明説明() (1.03克,3.0毫莫耳)之丙酮(2〇毫升)0溶液以瓊斯 (Jones)試劑(約 2M,7.5 毫升-Cr〇3,H2S.CU,h2〇) 一次 .處理並在室溫攪拌2小時。添加2 —丙醇(2毫升)以終止氧化 劑。反應混合物再以Et2〇稀釋,快速流經矽藻土及Si〇2 塾’並濃縮產生0·90克(88%,2.6毫莫耳)目的化合物。 FDMS : M 二342 ° 對 C18H18N205 分析計算値:C,63.15; Η 5·30; Ν, 8·18。貫測値·· c, 62 87; Η,5 56;〜Ν, 8 26。 (c )依循貫例1 ( e )之方法,使步驟(b )產物水解產生目的 化合物。 實例.3 / (18'211*,411*,58*,65*)-2-胺基雙環[3.1.0]己燒-2*,6- 一複酸-4 -膦酸單鹽酸鹽單水合物 (請先閱讀背面之注意事項再填寫本頁)
、1T P0
經濟部中央標準局負工消費合作社印製 (a ) 2 -氧代-4 -(二乙基)亞磷羧基雙環[3 . 1 . 0 ]己烷· 6 -羧 酸(1 S *,4R*,5S *,6S *)乙酯。實例 1 〇)產物(1.6 克,9.6 毫莫耳,),亞磷,,酸三乙酯(2.0克,12.0毫莫耳)於4.2克酚之 混合物在100 °C加熱隔夜。所4导反應混合物使用HPLC (己 烷/ EtOAc)純化,得2.7克(92%,8.9毫莫耳)目的化合 物。mp = 6 7-7(TC。FDMS : M + +1 二305 卜對 C13H2i〇6P 之 -38- 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210Χ 297公犮) 505623 Α7 R-7 經濟部中央標準局員工消费合作社印製 五、發明説明(36 ) 分析計算値:C,51.32; H,6.96,實測値:C,5111; η, 6.89。 (b)2-胺乙SS基-2-散基- 4- (二乙基)亞鱗複基雙環[31.0] 己烷-6-羧酸(1 S*,2R*,4R*,5S*,6S*)乙酯。KCN(3.2 克,49毫莫耳)、NH4C1(2.6克,49毫莫耳)及八12〇3(25 克)於C Η 3 C N之混合物在N 2下於Branson 3200超音波浴中 聲振1小時。接著添加步驟(a )產物(1.5克,4 · 9毫莫耳)並 再於4 5 °C聲振7 2小時。反應混合物經矽藻土過濾並且濾、液 濃縮至乾。所得中間物胺基腈溶於CH2C12中,冷卻至(TC 並以乙醯氯(0.5克,6.4毫莫耳-)及N,N -二異丙基乙胺(〇.8 克,6.4毫莫耳)處理。使反應在常溫進行1小時,接著混合 物分配於C H2 C 12及H2 0間。分離有機相,脱水(MgS〇4)、 過濾並減墨濃縮。粗產物以層析法(己燒^ / Et〇Ac )純化, 得1.0克5 5%)乙基-2-胺乙醯基-2-氰基-4-二乙基膦酸酯雙 壤[3 . 1 . 0 ]己烷-6 -竣酸酯(異構物a )及〇. 1 〇克(5 %)乙基-2 _ 胺乙SS基-2 -氰基-4 _二乙基膦酸酯雙環[3 . 1 . 〇 ]己燒_ 6 _複 S父醋(兴構物马)。(異構物A) : mp= 135 - 13 8 °C。FDMS : Μ +1= 373。之分析計算値:c, 51 61; H, 6·77; N,7.52。實測値:C, 51.89; H,6.78; N, 7.75。 (〇(18*,211*,411*,58*,68*)-2-胺基雙環[3.1.0]己烷 -2,6 -二羧酸_4,-,酸單鹽酸鹽單水合物。使步驟(1})產物 (異構物A)(0.08克’ 0.2毫莫耳)於3 〇毫升6N HC1中回流 4 8小時而製備目的化合物。濃縮粗產物並使用陰離子交換 管柱以1N H C1〉谷離而純化,收集q q 6克(9 9 %,〇 2毫莫耳), -39- (請先閱請背面之注意事項再填寫本頁 4. 、1Τ 本紙張尺度適用中國國家標準(CNS )八4規格(210χ 297公楚) 505623 Α7 Β-1 五、發明説明() 目的化合物。FDMS : Μ_+1=266。對 C8H12N〇7P · HC1· H20之分析計算値:C, 30 06; H, 4 73; N, 4 38。實測値: C,29.87; H,4.36; N,4.13。 * ’ 實例4 · (18*,25*,48*,511*,611*)-2-胺基-4-甲氧雙環[3.1.0]己 烷-2,6 -二羧酸 . H OMe ·
(請先閱讀背面之注意事項再填寫本頁) .#· 經濟部中央標率局員工消費合作社印製 (a ) 2 - N -第三丁氧羰基胺基_ 4 -羥基雙環[3 . 1 . 〇 ]己烷- 2,6 -二羧酸(1 S *,2 S *,4 S *,5 R *,6 R * )二乙酯。於含實例 / 1(c)產物(23.9 克,130 毫莫耳)之EtOH/H20(l : ί)(總體 積500 ¾升)攪拌溶液中,添加(nh4)2CO3(30.4克,390毫 „ 、 莫耳)再添加KCN(12.7克,195毫莫耳)。添加完後,反應 混合物在4 0 °C溫熱至反應完全。反應混合物冷卻至〇 °C, 以濃H C 1酸化至p Η二1,以EtOAc萃取非對映立體之5,-螺 乙内si:脲混合物。合併所有有機相,以食鹽水洗,以 MgS〇4脱水並減壓濃縮,得粗乙内醯脲之1 : 1混合物。此 7 ,, Γ 粗5 ’ -螺乙内醯脲(27.9克,1 1·θ毫莫耳)混合物於2N NaOH (2 7 5毫升)中回流加熱5天直至以T L C判斷反應完全。反應 混合.物冷卻至0 °C,以濃H C 1酸化至p Η〒:I再眞空濃縮至 -40- 本紙張尺度適用中國國家標準(CNS ) Α4規枱(210Χ 297公釐) 、1Τ &7 &7 38 505623 五、發明説明( 乾。所得固體再構成於100% Et〇H( 500毫升)中並冷凍至ο Τ。接著在使反應溫度維持在1 〇 °C之速率滴加S0C12( 120 克,1莫耳)至反應混合物中。添加完成後,反應回流加熱 隔夜b再眞空濃縮反應混合物並再構成於飽和NaHC03水溶 液·· T H F之1 : 1混合物(總體積500毫升)中。接著於反應 混合物中一次添加Boc2〇(1 18克,550毫莫耳)並在室溫攪 拌隔夜。反應混合物於眞空中還原並以EtOAc萃取粗N -B 〇 c二乙醚。合併所有有機萃取液,以η 2 〇及食鹽水洗, 以Κ2 C Ο 3脱水並濃縮,得120克粗產物。單離兩種非對映 立體異構物並經prep-HPLC( 100%己烷至50% EtOAc /己 烷)純化,得〗0 · 1 2克(2 6 %,2 8毫莫耳)泡沫狀所需產物° FDMS : λΤ+ 1 = 358。對 C17H27N〇7之分析計算値:C, 57.13; H,7.61; N,3.92。實測値:C,56.84; Η, 7·64; N, 3.96。 / (b ) 2 - N -第三丁氧羰基胺基_ 4 -甲氧雙環[3 . 1 · 〇 ]己烷-2,6-二羧酸(15*,28*,48*,511*,611*)二乙酯。於含步驟 (a)產物(0.50_克,1.4毫莫耳)之THF(30毫升)〇°C溶液中, 一次添加N a Η ( 0.0 7克,1.7毫莫耳),接著滴加甲基換 (0.2 1克,1.5毫莫耳)。使所得反應混合物溫至室溫並攪拌 隔夜。反應以Η 2〇稀釋並以Et〇Ac萃取產物。合併所有有 機相,以食鹽7_}〇洗,以K 2 C Ο 3脱水,減壓濃縮並以P C - •’ r ' TLC( 10% EtOAc /己烷至90% EtOAc /己烷)純化,得 0.12克(0·32毫莫耳,23%)所需產物。FDMS : M — +l=372。對 C18H29N〇7*析計算値·· ‘C, 58.21; Η,7.87; -41 - 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 、-0 經濟部中央標準局員工消费合作社印製 505623 Α7 Β7 經濟部中央標準局員工消費合作社印製
39-----五、發明説明() N, 3.77。實測値:C,58.69; Η,7·52; N,4.85 〇 (c) 2 -胺基-4-甲氧雙環[3.ι·〇]己燒-2,6-二致酸 (1S*,2S*,4S*,5R*,6R*)二乙酯。於含步驟(b)產物之 Et〇Ac(25毫升)〇°C溶液中吹入無水HC1氣體直至溶液達飽 和。所得反應混合物在0 °C攪拌1小時再減壓濃縮至乾。固 體溶於飽和NaHC〇3(aq)中且產物以EtOAc萃取。合併所有 有機相,以食鹽水洗,以K 2 C 0 3脱水,減壓濃縮並以卩(:-TLC( 10% EtOAc / 己烷至 1〇0〇/0 Et〇Ac)純化,得 〇 〇5 克 (0.18 毫莫耳,61%)所需產物。FDMS : M + +1 二271。h NMR (CDC13) : ^ 1.25 (t, J-7 Hz, 3H), 1.29 (t, J = 1 Hz, 3H),1.61 (t,J二3 Hz, 1H),1.80-1.95 (br m 3H),2.17:2.20 (m,1H),2.46-2.50 (m,2H),3.27 (s,3H),3.85-3.87 (m, 1H),4.15 (q, J二7 Hz, 2H),4.24 (q,J二7 Hz,2H)。13C NMR (CDC13) : cM3.96,14.11,20.82, 3 1.90, 33.96, 40.17, 56.00, 60.69, 61.26, 64.63, 82.14,172.14,174.85。對 C13H21N〇5 分析計算値:C,57.55; H, 7.80; N, 5.16。實測値·· C, 56.04; H,7.70; N,5.81 〇 (d) (lS*,2S*,4S*,5R*,6R*)-2-胺基-4-曱氧雙環 [3 . 1 . 0]己烷- 2,6 -二羧酸酯。步驟(c)產物(0.04克,0.1 1 毫莫耳)在IN NaOH/THF 1 : 1溶液(總體積10毫升)中於 室溫攪拌隔夜:/反應混合物以6N HC1酸.化至p Η = 1並濃縮 r 至乾。所得固體再構成於pH-2之水中,施加至Dowex® 50X8- 100陽離子交換樹脂上,以10%吡啶/h2〇溶離,得 O. 012 克(3 7%,0.06 毫莫耳)目的產物‘。mp = >275 °C。, -42 - 本紙張尺度適用中國國家標準(CNS ) A4規枱(2丨0X 297公H (請先閱讀背面之注意事項再填寫本頁) 衣·
、1T 505623 A7 40 五、發明説明( FDMS : M — +卜216。4 NMR (D2〇/K〇Ci) : 〇Μ·〇8-1·14 (m,2Η), 1.74-2.07 ’(m, 3Η),3.05 (s,、3H),3.65-3.75 (m, 1H)。對 C9H13N05 · 〇·2 NaCl分析之計算値:C, 47.64. Η * 1 ’ ^ 5.78;队6.17。實測値.:(:,47.75;;«,5.74;1^,7.49。 • 實 05 · (13*,25*,5 11*5611*)-2-胺基-4-氧戎雙環[3.1.〇]己烷-2 , ό •二複酸
CO Η (請先閱讀背面之注意事項再填寫本頁) 衣 訂 經濟部中央標準局員工消费合作社印製 (a ) 2 - Ν -第二丁氧羰胺基-4 -氧’代雙環[3」〇 ]己烷_ 2 , ^ · 一叙§父(15*,2 8'5 11*,611*)二乙酷。實例4(^)產物(〇〇5 克,1.4笔莫耳)足c H 2 C 12 ( 1 5耄升)溶液在室溫攪拌,一 次添加重鉻酸吡啶鹽(1.60克,4.2毫莫耳)。所得反應混合 物在室溫攪拌隔夜。反應以EtOAc稀釋並經矽藻土過濾以 移除鉻副產物。眞空濃縮濾液並經P(^T]LCn()% Et〇Ae/ 己烷至2〇% EtOAc/己烷)純化,得〇 49克(1 38毫莫耳, 98%)白色泡床產物。FDMS ··,十356。對 刀析计异値· C,57.46; Η,- 7~.〇9; Ν, 3.94。實測値:C, 57.60; Η,7.14; Ν, 4.03。 (b)(lS‘,2S'5R'DR*)-2•胺基 _4_ 氧代雙環[31〇] -43- 本纸张尺度通州T囤圏冢標準(CNS ) Λ4規枋(210X297公楚) 505623 A7 __ \¥1 -41 ~ -----五、發明説明() 己烷-2,6-二複酸。步驟(a)產物(ο」?克,1 〇4毫莫耳)於 EtOAc ( 3 0愛升)之0 C落液吹入無水η c i氣體直至飽和。所 得反應混合物在〇 °C攪掉1小時再眞空濃縮至乾。所得固體 再構成於1 〇耄升IN Na〇H中並攪拌隔枣。反應混合物以6N HC1調整至pH = 2,施加至Dowex® 50X8_1〇〇陽離子交換樹 脂上並以1 〇 %吹哫/ Η2 0溶離產物。產物自η 2〇再結晶, 得0.06克(3 1 % ’ 0.30毫莫耳)所需產物。mp二分解>210 °C。FDMS : Μ + 1 = 200。對 c8H9N05 分坼計算値·· C, 48·25; H,4.55; N,7.03。實測値:c, 4819; H, (46; N, 7.16。 · * 貫例ό(18*,28*,511*,611*)-2-胺基-4-[反]-羥亞胺雙環[3.1.0] 己烷- 2,6-二竣酸及(lS*,2S*,5R*,6R*)-2 -胺基- 4-[順]-羥亞胺雙環[3. 1.0]己烷_2,6-二羧酸
-OH (請先閱讀背面之注意事項再填寫本頁) 4 經濟部中央標準局員工消f合作社印製 N.
c〇2H H〇' N 反
c〇2H 順 (a ) 2 -胺基'4「氧代雙環[3 1 〇 ]己烷_ 2,6 -二複酸 (1 S *,2 S *,5 R *,6 R * )二乙酯 μ 實例 5 ( a)產物(〇 3 7 克, 1.0 4愛莫耳)於E t〇A c (:) 0堂升)之〇 °c溶液吹入無水η C 1氣 體直至飽和。反應混合物在0 °C攪拌1小時。反應混合物以 -44- 本纸張尺度適用中國國家標準(〔”5)/\4規格(210乂 297公浼) 505623 經濟部中央標準局員工消费合作社印製 A7
BQ 42 — ~~—-—·~« 五、發明説明() 飽和N a H C 03水;容液稀釋並以e 10 A c萃取產物°合併所有有 機相,以食鹽水洗,以K2 C 0 3脱水並眞空濃縮,得所需中 間物(0.36 克,1.4 毫莫耳,1〇〇〇/0)。FDMS : IVT+1:=256。 對〇1211171^〇5*0.2 112〇分析計算値:(:,5 5.68;11,6.78;]^, 5.41。實測値:C, 55.47; H, 5.91; N, 5.24。 (b ) 2 -胺基-4 -羥亞胺雙環[3 · 1 . 〇 ]己烷-2,6 -二羧酸 (15'25'411*,611*)二乙酯。於室溫下在含步驟(3)產物 (0·36克’ 1.4毫莫耳)及NaOAc(0.23克,2.、8毫莫耳)之 EtOH/H2〇3 : 1混合物(總體積20毫升)溶液中,添加羥 胺鹽酸鹽(0.15克,2.1毫莫耳)_並在80 T加熱1小時,添加 NaHC_〇3水溶液在反應混合物中,以Et〇Ac萃取產物,以食 鹽水洗,以K 2 C Ο 3脱水並眞空濃縮,得e及Z異構物之2 : 1 混合物。以 PC-TLC(10% EtOAc/己烷至67% EtOAc/ 己燒)純化得乾淨產物。反式異構物:〇18克(0 67毫莫 / 耳,56%)。FDMS : IVT+1 二 271。對 C12H18N205 · 0.35 CH2C12 之分析計算値:c,49.44; H,6.28; N, 9.34。實測 値:C,49.62; Η,5·89; N,9.39。順式異構物:0.09 克 (0.33 氅莫耳,2 8 %),mp = 135 - 137 °C。FDMS : M + + 1 二271。對C丨2H I 8N2〇5 · 0.1己烷分析計算値:C,54.26; H, 7.0 1; N,10.04。實測値·· C, 54.03; H, 6.71; N,10.14。 (c)( 18*,28*,511*,6尺*卜2-胺基_4_[反]-羥亞胺基雙環 [3 . 1 . 0]己烷_2,6_二羧酸。-步_驟(b)之反式-肪(〇 13克, 0.48毫莫耳)在室溫下於1N NaOH : THF 1 : 1混合物(總 體積2 0毫升)中攪拌4天。再以η 2〇稀釋反應混合物並以, -45- 本ί氏張尺度適用中國國票準(CNS ) Λ4規枱(210Χ 297公釐)~~ ~ ' ' (請先閱請背面之注意事項再填离本頁) 4.
、1T 505623 第87107483號專利申請案 中文說明書修正頁(91年3月) 補充
j ΰΐ. 3. ^ i午f\
EtOAc洗滌產物(3X)以移除有機雜質。水層以1N HCi調整 至pH= 10並真空濃縮。固體再構成於Η"中並以陰離子交 換層析法(Bio-Rad® AG1-X8 :以3N Ac0H溶液)純化,自 H20/2-丙醇(1 : υ再結晶,得〇 〇7克(〇 33毫莫耳,68%) 產物。mp=分解 >260 C 。FDMS : M++l=215 。對 C8H1()N205 · 〇·15 Η20 分析計算值:C,44.3 0; Η,4·79; Ν, 12.91。實測值:C,44.53; Η,4.48; Ν,12.51。 (d)(lS*,2S*,5R*,6R*)-2-胺基-4-[順]-羥亞胺基雙環 [3.1.0]己烷-2,6 -二羧酸。利用0.085克(0.31毫莫耳)步驟 (b) 之順式_肟產物,而反應條件、操作及單離均同步驟 (c) ’ 件 〇·〇4 克(0.19 愛莫耳,60%)。mp:分解 > 2 5 0 °C。 FDMS : M++l=215。對 C8H10N2O5 · 0.15 NaCl分析計算 值:C,43.10; Η,4·52; N,12.57。實測值:C,43.46; H, 4.74; N,11.75。 實例7 (18*,211*,48*,53*563*)-2-胺基-4-氟雙環[3.1.〇]己烷-2,6 -二羧酸 Η
(3)2-〜第三丁氧羰胺基-4-氟雙環[3.1.0]己烷-2,6-二 羧酸(13*,211*,43*,53*,68*)二乙酯。於含實例4(&)產 -46- 本紙張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐) 505623 A7 44 —-——_-^ --- 五、發明説明() 物(0.50克,1.40毫莫耳)之cH2Cl2(25毫升)0。(:溶液中, 一次添加二乙胺基硫三氟化物(DAS τ )。使所得反應混合物 溫至室溫並攪拌隔夜。反應以1〇% NaHC〇3水溶液稀釋並 以EtOAc萃取產物。合併所有有機相,以食鹽水洗,以 K2C〇3 脱水並經PC-TLC(1〇〇/0 EtOAc / 己烷至20% EtOAc) 純化’得0.38克(1·〇6毫莫耳,74%)透明無色油之所需產 物。FDMS : JVT+1=360。對 Ci7h26N〇6 兰析計算値:c, 56.81; Η,7·29; N,3.90。實測値:c,56 79; η,7 42; N, 4. 1 1 〇 (b )2-胺基-4-氟雙環[3丨〇]己烷_2,6-二羧酸 (18'211*,48'58*,65*)二乙酯。步驟(3)產物(033 克,0.92毫莫耳)於EtOAc(3〇毫升)之〇。〇溶液通入無水 H C 1氣體直至飽和。所得反應混合物在〇。〇攪拌1小時,反 應混合物以飽和NaHC〇3水溶液洗並以Et0Ac萃取產物。合 併所肴有機相,以食鹽水洗,以K2 C Ο 3脱水並眞空濃縮, 得0.23克(〇·89毫莫耳,96%)所需產物。FDMS :
M、l:260。對 C12H17FN〇4 分析計算値:C, 55 59; H 7.00; N,5.40。實測値:C, 55.56; H,6.79; N, 5.21。 經濟部中央標準局員工消贽合作社印製 ------ (請先閱讀背面之注意事項再填寫本頁 、11 (c)(lS*,2R*,4S*,5S*,6S*)-2 -胺基-氟雙環[3」〇] 己烷-2,6 -二複酸。步骤(b )產物(〇. 12克,〇 46毫莫耳)於 IN NaOH : 丁HF,丨:1混合物(總體積20毫升)溶液在室溫 攪拌隔夜。接著反應混合物以6N HC1調整至pH=i2並經陰 離子交換層析法(Bio-Rad® AG1-X8離子交換樹脂,3N乙龄 作爲溶離液)純化。自Η 2 0 / 2 /丙醇(1‘ 丨)再結晶,得 -47- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X29?公楚) )05623 五、發明説明( 4Γ A7 &7 0.04克(0.20¾莫耳,,49%)所需產物。mp二分解>26〇。〇。 FDMS : Μ + 1 =204。對 C8H1()FN04 · 0.45 NaCl 分析計算 値·· C,41.87; H,4.39; N,6.1〇。實測値:C,4191; η, 4·00; N, 5.76。 實钩8、 ·(18*;25*,4&*,511*,68*)-2,4-二胺基雙環[31〇]己烷- 2,6 -二羧酸 —
c〇,h ---------'·私-- (請先閲讀背面之注意事項再填寫本頁) 、-口 經濟部中央標準局員工消费合作社印製 —(a ) 2 - N -第二丁氧羰胺基_ 4气對-曱苯磺醯氧基)雙環 [J.1.0]己烷-2,6-二羧酸(18* 28*,4§* 511*,611*)二乙 醋。對-曱苯磺醯氯(5.3克,28毫莫耳)添加至含實例4(a) 產物(5.0克,1 4毫莫耳)之吡啶(2 5毫升)溶液中且所得反 應混合物在罜溫攪拌隔夜。反應混合物以尽t〇Ac(i⑼亳升) 稀釋並以飽和。8〇4水溶液洗以移除吡啶。有機相以食鹽 水洗,以¥〇4脱水並減壓濃縮,得粗產物,#以$办層 析法(HPLC qa% Et〇Ac/己烷至5〇% Et〇Ac/己烷^ 化,得6.55克(9 1%,12·8毫莫耳)白色泡沫之所需產物。 FDMS : Μ·+1 二5 12。對C24H33N09S分析計算値:C, 56 35: Η, 6·50; N,2.74。實測値:C,56·48; H,6:44; N,2.60。 -48- 本纸張尺度適用中國國家標準(CNS ) Λ视枱(210X 297公#_ ) 505623 經濟部中央標準局員工消费合作社印製 A7 五、發明説明() (b) 2-N-第三丁氧羰胺基-4-疊氮雙環[31 〇]己烷_2,6_ 二幾酸(15*,28*,4反*,511*,65*)二乙酯。含步骤(&)產物 (6·:)5克’ 12.4¾莫耳)及NaN3(2.42克,372毫莫耳)之 DMSO ( 1 5愛升)溶液在3 5 °C溫熱3天。反應混合物以η 2 〇 稀釋並以EtOAc萃取產物。合併所有有機相,以食鹽水 洗’以MgS〇4脱水並減壓濃縮,得粗疊氮化物,其經Si〇2 眞空過濾純化(20% EtOAc/己烷至50% Et0Ac/己烷), 得4.68克(98%,12.2毫莫耳)蠟狀固體*之所需產物。 FDMS ·· Μ +1=5 12。對 C17H26N4〇6 · 〇.1 己烷分析計算 値·· C,54.06; H,7.06; N,14J33。實測値:c, 53·94; H, 6.88; N, 14.30。 (c) 2-N -第三丁氧羰胺基-4 -胺基雙環[3.1.0]己烷-2,6- 二羧酸(18*,28*,411*,511*,68*)二乙酯。三苯膦(2.90 克,1 1毫莫耳)一次添加至含步驟(b)產物(3.5克,9.2毫莫 / 耳)之T H F / Η 2〇(5 : 1 )溶液中並在室溫攪拌隔夜·。反應 混合物以EtOAc稀釋並以〇.5N NaOH洗(3Χ)。合併有機 相,以Η 2〇再以食鹽水洗,以κ 2 C Ο 3脱水,減壓濃縮並以 81〇2層析法(那1^:81〇2(10%£(0八(:/己燒至50%£1:0八。 /己烷))純化,得2.03克(62%,5.7毫莫耳)泡沫狀所需產 物。FDMS : Μ — +卜357。對C17H28N2〇6分析計算値:C, 57.30; H,7.92;、N, 7.86。實測値:C, 57.02; H, 7.73; N, 7.72。 — (句(15*,2 8*,4!1*,511*,68*)-2,4-二胺基雙環[3.1.〇] 己燒-2,6 -二羧酸。步驟(c )產物·‘於1N HC1中回流加熱隔, -49- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公楚) (請先閱竣背面之注意事項再填寫本頁) Φ
、1T V · 2 6 5 ο 5 A7 一 47 ' ---—-一~ __ 五、發明説明() 夜。反應混合物以IN NaOH調整至pH = 2並以陽離子交換 層析法(Dowex® 50X8-100 : 1 0%吡啶/h2〇)純化。所得 產物自2 -丙醇/ Η2〇(1 : 1)中再結晶,得〇.〇9克(45%, 0.45毫莫耳)白色固體之所需產物。mp = >275 °C。FDMS : IVT+I 二 201。對 C8H12N2〇4 · 〇·5 H20 分析計算値:c
45·93; H,6.26; N,13.39。實測値:C,45.66; H,7.45; N 13.32 0 實例9 _ (lS*,2S*,4R*,5R*,6S*)-2-胺基_4-疊氮基雙環[3. i 〇] 己烷-2,6 -二羧酸 / . (請先閱讀背面之注意事項再填寫本頁)
訂 經濟部中央標準局員工消費合作社印裝 含貫例8(b)產物(0.25克,〇·65毫莫耳)之EtOAc(30毫升) 溶液冷凍至0 並充入無水H C 1氣體直至溶液達飽和。反應 混合物在0 C攪拌2小時,濃縮至乾且所得固體於川 NaOH : THF 1 : 1混合物(總體積2〇毫升)中於室溫攪拌隔 夜··。減壓移除T H F ,水溶液混合物以1N HC1調整至 PH=12,並以嗲灕子交換層析法(Bi〇'Rad® agi-XS :乙酸 酯態轉化成氫氧化物態,以.3N乙酸溶離)純化,得〇. 1〇克 (0.44笔莫耳’ 6 8 %)所需產物。爪p二分解> 2 7〇 °C 。 FDMS : M — +1 二227。對(:8Η10Ν:Ό4 · 0.2, AcOH分析計算 -50- 505623 A7 仏7 48五、發明説明() 値:C,42.36; H,4.57; N,23.52。實測値:C,41.96; H, 4.54; N, 23.55 〇 _ ' 實例1 0 (lS*,2S*,4R*,5R*,6S*)-2 -胺基-4-乙醯胺基雙環 [3 · 1 . 0 ]己烷-2,6 -二羧酸
H ^HAC
(請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消f合作社印製 (a)2-N -第三丁最羰胺基-4 -乙醯胺基雙環[3 . 1 . 0]己烷- 2,6-二羧酸(18*,28*\411*,511*,68*)二乙酯。.乙醯氯 (0.09克,1.1毫莫耳)滴加至含·實例8(c)產物(0.35克,1.0 * > 毫莫耳)及三乙胺(0.20克,2.0毫莫耳)之CH2C12(20毫 升)0 °C溶液中,且使所得反應混合物溫至室溫並攪拌隔 夜。反應混免物以Et2〇稀釋,以NaHS〇4水溶液再用食鹽 水洗,以MgS〇4脱水並眞空濃縮,得粗乙醯胺,其以卩(:-TLC( 1 0% EtOAc /己烷至67% EtOAc /己烷)純化,得 0.35克(8 8%,0.88毫莫耳)白色固體之所需產物。mp=分 解 8 5 - 9 5 °〇。[0\48:1^+1=399。對(:19:»3(^2〇7分析計 算値:C,57.27; H,7.58; N-,子.03。實測値:C,57.41; H, 7.28; N,6.94。 (b ) ( 1 S *,2 S *,4 R * , 5 R * , 6 S * ) -· 2 -胺基4 -乙醯胺基雙環, -51 - 本紙張尺度適用中國國家標準(CNS ) Λ4規枱(210X29?公浼) 505623 μ \νι ΛΟ~" --------- 五、發明説明() [J . 1 . 0 ]己- 2,6 ·二幾酸。含步驟(a )產物(〇 3〇克,〇 75 毫莫耳)之Et〇Ac ( 3 0毫升)溶液冷;東至〇。〇並吹入無水η c 1 氣體直至溶液達飽和。反應混合物在〇。(3攪拌2小時,濃縮 至乾,且所得固體於1N Na〇H : 丁 H F 1 : 1混合物(總體積 2 0毫升)中於室溫攪拌隔夜。減壓移除τ η F,水性混合物 以IN HC1調整至ρΗ = 2並以陽離子交換層析法(Dowex® 5 0X8-100 ’以1 〇%吡啶/h2〇溶離)純化。自h2〇/2 -丙 醇(〗.1 )再結晶’得〇 〇9克(〇 · 3 7毫莫耳,_5 0 % )所需產 物。mp 二 >275°C。FDMS : M —+1=243。· 0.3 NaCl 分析計算値:c, 46.24; Η,. 5.43; N, 10.78。實測 値·· C,45.93; Η,5.50; Ν, 10.88。 . 實例1 1 (1 S *,2 S *,4 R *,5民* , 6 s * ) - 2 -胺基-4 -苯甲醯胺基雙環 [3 . 1 . 0 ]己烷 _ 2,6 -二羧酸 ’
經濟部中央標準局員工消费合作社印製 (a ) 2,- Ν -第三丁氧羰胺基-4 -苯甲醯胺基雙環[3 . 1 . 0 ]己 知-2,6-二羧酸(18*,23*,4尺:^511*,65*)二乙醋。苯甲醯 虱(〇. 1 6克,].]毫莫耳)滴加至含實例g ( c )產物(〇 35克, 1.〇耄莫耳)及三乙胺(0 2〇克,2 〇毫莫耳‘)之C H2Cl2(20毫 氏張尺) ;^^7^ 297公楚) ---- 50505623 A7 B7. 五、發明説明( 升)〇5c溶液中’使所得反.應混合物溫至室溫並攪拌隔夜。 反應混合物以Et2〇稀釋,以NaHS〇4水溶液再用食鹽水 洗,以MgS〇4脱水並眞空濃縮,得粗醯胺,其以卩匸_ TLC(10% EtOAc /己烷至67% Et〇Ac/己烷)純化,得 0.3 1克(67%,0.67亳莫耳)白色泡沫之所需產物。FDMS : M、1 二461。對 C24H32N2〇7 分析計算値:c, 62 59; H, 7.00; N, 6.08。實測値:c, 62 75; H,6 7〇; N,5 99。 (13)(15*,25’,411*,511*,68*)-2-胺基_4-.苯甲醯胺基雙 環[3 . 1 ·0]己烷-2,6-二羧酸。步驟(a)產物(〇 3〇克,〇 75 [ 毫莫耳)於EtOAc (3 0毫升)之溶液冷凍至〇。〇並吹入無水 H C 1氣體ιΕ芏;谷液達飽和。反應混合物在〇 t攪掉2小時, 濃縮至乾且所得固體於1N Na〇H : T H F 1 : i混合物(總體 私2 0笔升)中於至溫攪拌隔夜,減壓下移除了 η F且水性混 合物以IN HC1碉整至ρΗ==2並以陽離子交換層析法 (Dowe,50X8-100,以]〇% 吡啶/Η2〇 溶離)純化。’自 Η』/一·】醇(1 · 1)再結晶,得0095克(Q3i毫莫耳·, 5 8%)所需產物。11113=分解>275。〇。?1:)奶:^+1=3〇5。 對C〗5 Η丨6Ν2〇5 · 0.3 2 -丙醇分析計算値:c,59 25; η, 經濟部中央標準局員工消費合作社印製 5·75; N,8.69。實測値:c,59 5〇; H,5 65; N, 8 32。 實例1 2 (1S*,2S*,4R* JR*,6S*)_2_ 胺基·4·(甲磺醯胺基)雙環 [j . 1 . 0 ]己 feL - 2,6 -二 酸- -53-本纸張尺度適用中國國家標準(CNS ) Λ4規枱(210x 297公浼) 505623 A7 B-7 — 五、發明説明()
(a ) 2 - N -第三丁氧羰胺基-4 -(甲磺醯胺基)雙環[3 . 1 .0 ] 己烷- 2,6 ·二羧酸(1、S *,2 S *,4 R ' 5 R *,6 S * ).二乙酉旨。甲磺 醯氣(0. 1 3克,1. 1毫莫耳)滴加至含實例8 ( c )產物(0.35 克,1.0毫莫耳)及三乙胺(0.21克,·2.0毫莫耳)之CH2C12 (2 5毫升)0 °C溶液中且所得反應混合物在0 t攪摔· 1小時。 反應混合物以EtOAc稀釋,以’ NaHS04水溶液再用食鹽水 洗,以MgS〇4脱水並眞空濃縮,得粗甲磺醯胺,其以?匸-T L C ( 1 0 % EtOAc /己烷至67% EtOAc /己烷)純化,得 0.44克(99°/。,1.0毫莫耳)白色泡沫之所需產物。FDMS : Μ + 1-435。對 C 1 sH30N2O8S 分析計算値:C,49.76; Η, 6.96; Ν, 6.45; S,7.38 。實測値:C,50.04; Η,6.68; Ν,6.21; S, 7.38。 經濟部中央標準局員工消費合作社印製 (b ) ( 1 S *,2 S *,4 R * , 5 R * , 6 S * ) - 2 -胺基-4 -(甲磺醯胺基) 雙環[3 · 1 . 0 ]己燒-2,6 -二複酸。步驟(a )產物(0 · 4 0克, 0·92毫莫耳)於EtOAc(3 0毫升)之溶液冷凍至0°C並吹入無 , 1 * 水H C 1氣體直至溶液達飽和^反應混合物在0 °C攪拌2小 時,濃縮至乾且所得固體於1N NaOH : T H F 1 : 1混合物 (總體積20毫升)中於室溫攪拌隔夜。減愚下移除THF,水, -54- 本紙張尺度適用中國國家標準(CNS ) Α4規枱(210Χ297公釐) 505623 A7 ---^ _ 8-7 五、發明説明(52 ) 性混合物以1N HC1調整至p H = 2並以陽離子交換層析法 (Dowex® 50X8-100,以1〇%吡啐/出〇溶離)純化。自 H2〇/2-丙醇(丨:1 )再結晶,得〇 13克(〇 46毫莫耳,5〇%) 所需產物。mp 二 >275 °C 。FDMS : M — +1 二 279。對 C9H14N2〇6S 分析計算値:c,38 84; H, 5 〇7; n, 10.07。實 測値:C,39.01; Η, 5·21; Ν,10·07。 . • 實例1 3(:1^’25'41^,5尺、68*)-2 -胺基- 4- (甲胺-談胺基)雙環 [3 . 1 · 0 ]己烷-2,6 -二羧酸 -----丨-I-I蠖 —I (請先閱讀背面之注意事項再填寫本頁) Η ΗΝ JLisj^Me
、1T 經濟部中央標準局員工消费合作社印^ (a ) 2 - N -第三丁氧羰胺基_ 4 甲胺羰胺基)雙環[3 .丨· 〇 ] 己:^-2,6-二羧酸(18*,28*,411*,511*,65*)二乙酯。異氰 酸曱酯(0·07克’ 1.2毫莫耳)滴加至含實例8(c)產物(〇 μ 克,1.0毫莫耳)之CH2C12(25毫升)0°C溶液中並使所得反 應混合物溫至室溫並攪拌隔夜。反應混合物以EtOAc稀 釋’以NaHSC^Jo溶液再用食鹽水洗,以MgSCU脱水並眞空 濃縮,得粗甲基脲,其以p C,丁 L C ( 1 〇 % ElO Ac /己燒至 50% EtOAc/己烷)純化,得0.35克(85%,〇·85毫莫耳)白 色泡沫之所需產物。FDMS : ΓνΓ+ 1二414‘ °對C 19H3 1 N3〇7, -55- 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇X 297公趁) 505623 A7 53 五、發明説明() 〇’5 H2〇 分析計算値:C, 54·01; Η, 7·6:5; N,9.95。實測 値·· C,53.81; Η,7 52; Ν, 1〇 64。 k iMUS ’2S'4R*,5r*,6S*)-2 -胺基_4_(甲胺羰胺基) 又衩^.^1.0]己烷-2,二羧酸。含步驟(a)產物(0.30克, 〇·72 &莫耳)(Et〇Ac(3〇毫升)溶液冷凍至〇。〇並吹入無水 H C 1氣直主落液達飽和。反應混合物在〇 π攪拌^小時, 乾且所得固體於lNNa0H : THF L:1混合物(總體 毛、2 0毛升)中在室溫攪拌隔夜。減壓移除τ η f,水性混合 物:WN HCl’整、spH=:2並以陽離子交換層析法(D〇獸? 5'X8;100, ^1〇%P^/H2Q^)^,b 〇 ^h20/2^ 酉予(1 · 1)再結晶,得0 12克(,0·46毫莫耳,64%)所需產 物 mp >27) C。FDMS : M + +l=258。對 C10H15N3O5 · 0.1 ho分析計算値:c,Μη; H,5吒n,10力。實測 値.C, 46.03; Η, 6·01; N, 16.12 。 實例14 / (1S ’一 S ,4R ,5R'6S*)-2 -胺基- 4- (Ν,Ν·二環丙基甲 胺基)雙環[3 .1 . 0 ]己烷_ 2,6 _二羧酸 -------- --^讀—丨 (請先閱讀背面之注意事項再填寫本百() 、1Τ •Ί 經濟部中央標準局員工消费合作社印製 Ρ>
-56- 本纸張尺度適用中國國家標隼(CNS ) Λ4規格(210X297公蝥) 505623 A7 B7 五、發明説明(54 ) 一 Γ^φ — (請先閲讀背面之注意事項再填寫本頁 (a ) .2 - N -第二丁氧藏胺基_ 4 - (N, N -二環丙基甲胺基)雙環 己少元-2,6_ 一 lkfe(lS*,2S*,4R* 5R* 6S*)二乙 知。%丙基甲基溴(0.27克,2.0毫莫耳)在室溫下滴加至含 實例8(c)產物(0·32克,〇.9〇毫莫耳)及三乙胺(〇 3〇克, =〇亳莫耳)之CH3CN(25毫升)溶液中,且所得反應混合物 4見拌夜。反應混合物眞空濃縮並以p C _ τ l C ( 1 0 % EtOAc /己烷至6 7 % Et0Ac /己烷)純化,」寻〇 3 3克(7 8 % ’ 〇·7〇宅莫耳)淡黃色油之所需產物。FDMS : Μ + 1 — 465。對 C25H4()N2〇6 分析計算値:c,64 63; 8·68; N,6.03。實測値:C,64.38; Η, 8·60; N, 5.93。 、11 (13)(18*,25*,411*,5反*,6。)-2_胺基_4_(比1二環丙 基甲胺基)雙環[3· 1.0]己烷_2,6_二羧酸。步驟(a)產物 (0.28兄,0.61¾莫耳)於Et〇Ac(30毫升)之溶液冷凍至〇°c 經濟部中央標率局員工消费合作社印製 並0人入典水H C 1氣體直至溶液達飽和。反應混合物在〇 〇c攪 拌4小時,濃縮至乾且所得固體於in Na〇H : T H F 1 : 1混 合物(總體積20毫升)中在室溫攪拌隔夜。減壓移除THF, 水性混合物以_ 1 N HC1碉整至ρ η = 2並以陽離子交換層析法 (Dowex® 5 0X8- 100,以 1 〇〇/〇 吡啶 / η2〇 溶離)純化,自 Η2〇/2-丙醇(1 : 1)再結晶,得〇 15克(〇 49毫莫耳,8〇%) 所需產物。mp二分解 >270 °C。FDMS : Μ‘+ 1 =309。對 C16H2:1N204 · Η2〇分析計算値:c, 6〇 21; Η,7 96; Ν, 8 · 7 8。貫測値:C, 5 9.9 2; Η, 7 ."9 9; Ν,8.9 3。 實例1 5 (1 S *,2 S *,5 R *,6 S * ) - 2 -胺基-4 - Ζ _ 羧亞‘甲基雙環[3 . 1 . 〇 ρ -57- 本纸張尺度適用中國國家標举(CNS)A4規枱(2Κ)>< 297公费) 505623 經濟部中央標準局員工消f合作社印製 五、發明説明( 55 A7 W1
己鍵· - 2,6 --—幾酸 (lS*,2S*,5R'6S*)-2 -胺基 _4'E-羧亞曱基雙環[31〇] 己Ί - 2,6 - —幾酸 Άη Η ' · H〇 C
HO C
C〇h
異構物B ” CO H
Z (a)2-(N -第三丁氧羰基)胺基(.芊氧羰基)亞曱基雙環 [^•1,0]己:>:”2,6-二#复酸(18*,28*,411*,68*)二乙@旨異構 物A及B。〇°C下添加雙(三甲基矽烷基)醯胺鈉(4·2毫莫耳) 至含二乙基亞臂竣基乙酸苄酯(1.2克,4.2毫莫耳)之無水 甲苯落液中而製備二乙基亞嶙複基乙酸_ g旨鋼鹽。此鋼鹽 在〇 °C下快速添加至含實例5 ( a)產物(1. 〇克,2.8毫莫耳)之 典水甲木洛液中並攪拌1 5分鐘。使反應溫至室溫並攪拌至 以T L C測定反_應完全。添加in HC1並使用乙酸乙酯萃取反 應混合物。合併之有機層以NaCl水溶液並以MgS〇4脱水。 有機相經濃縮且粗產物使用HPLC(EtOAc /己烷)純化,得 1.3克(94%)兩種異構物之混合物。FDMS : Μ、1 =486。對 匸26^133川〇8 分,.析計算値·· C,64.05; Η, 6·82; N, 2.87。實 測値:C, 64.04; H,6.87; Ν,·2γ96。 (b ) 2 -胺基-4 - Ε -(苄氧談基)亞甲基雙環[3」〇 ]己燒· 2,6 -二羧酸(1 S *,2 S *,5 R *,6 S * )‘二乙酯異構物A及2 -胺基 -58 - 本紙張尺度適用中國國家標举(CNS ) A4規枱(210X 297公釐) i衊—I (請先閱讀背面之注意事項再填寫本頁)
.1T 505623 A7 B-1 五、發明説明() -4-Z-(芊氧羰基)亞甲基雙環[3」〇]己烷·2,6_二羧酸 (18*,2 5*,411*,65*)二乙酯異構物^。在0^:將無水;9(::1 氣體打入含步驟(a)產物(0.4克,〇82毫莫耳)之Et〇Ac溶 液中。使反應溫至室溫並攪掉直至以T l C判斷反應完全。 有機相分配於NaHC〇3水溶液上,以k2 C〇3脱水,並眞空 農縮。以HPLC(EtOAc/己烷)純化得〇 154克(48%)異構 物A及〇. 13克(4 1 %)異構物B。 異構物 A : FDMS : M、l = 388。對(:211125%06 分析計算 値:C,65.10; Η,6·50; N,3.62。實測値:c,64.91; H, 6·40; N, 3.83 〇 _ 異構物 B : FDMS : M —+1 = 388。對(:2#25%〇6+0.5 當量 CH2C12 之分析計算値:C,60 07; H,6.1〇; N, 3.26。實測 値:C, 60.33; Η,6·05; N, 3.43。 (c) (lS*,2S*,5R*,6S*)-2 -胺基-4-Ε-羧亞曱基雙環 / 經濟部中央標準局員工消费合作社印製 -- (請先閲讀背面之注意事項再填寫本頁) [3 . 1 .0]己坑- 2,6 -二羧酸。步驟(b)產物異構物Α·(0.134 克’ 0·35毫莫耳)於5毫升2Ν NaOH及2毫升THF中攪拌5小 時。反應以1 N HC1調整至ρ η = 7並濃縮至乾,所得固體再 構成於ρΗ = 1 0之水中並施加至陰離子交換樹脂(Bi〇_Rad® AG1-X8,以2N乙酸溶離)而得0 038克(45%)所需產物。 FDMS : M、l=242。對(:1()1^1以06+〇.14 當量 NaCl 分析計 算値:C,48.16;,Ή,4.44; N 5.62。實測値:C,48· 15; Γ ? ' 4·29; N, 5.36。 . (d) (lS*,2S*,5R*,6S*)-2 -胺基-4-Z_ 羧亞曱基雙環 [3. 1.0]己烷-2,6-二羧酸。步驟(b)產物(0.107克,〇·28毫( -59- 本纸張尺度中關家料·( 505623 A7 五、發明説明() 莫耳)於5毫升2N _NaOH及2毫升THF中攪拌5小時。反應以 1 N H C1調整至p Η = 7並濃縮至乾,所得固體再構成於 ΡΗ= 1 〇之水中並施加至陰離子交換樹脂(Bi〇-Rad® AG1-,以2N乙酸溶離),得0.050克(75%)所需產物。 FDMS : M —+1 二 242。對 CwHhNC^+I.O 當量 h20 分析計算 値:C,46.34; H, 5.06; N,5.40。實測値:c, 46.43; H, 5.04; N,5.45。 · · 實例1 6 (18*,28*,511*,68*)-2-胺基-4-亞曱基雙環[3.1.〇]己烷- 2,6 -二幾酸 」· · i磉—丨 (請先閱讀背面之注意事項再填寫本頁)
經濟部中央標準局員工消f合作社印製 (a ) 2 - ( N -第三丁氧藏基)胺基_4·亞曱基雙環[3」〇]己 燒-2,6 -二羧酸(〗S *,2 S *,5 R *,6 S * )二乙酯。雙(三甲基矽 基)酸胺鈉(4 · 2毫莫耳)在〇 °C添加至含溴化甲基三苯鳞 (15克,4.2毫莫耳)之無水THF漿液中,於反應容器中添 加含實例5 (a)專物(0.75克,2· 1毫莫耳)之無水THF溶液並 r 在0攪拌隔夜。添加IN HCldi使用乙酸乙酯萃取反應混 合物。合併有機層,以NaCl水溶液洗並以MgS〇4脱水。有 機相經濃縮且粗產物使用HPLC ( EtOAc X己烷)純化,得/ -60- 本紙張尺度適用中國國家標準(CNS ) A4規枋(210X297公犮) 505623 A7 ___ B7
Ho —丨― -— ----— ________ 五、發明説明() ^ —d€T (請先閱讀背面之注意事項再填寫本頁 〇·52 克(7〇〇/0)所需產物。FDMS : Μ + +ι=354。 (b)(lS*,2S'5R*,6S*)-2 -胺基 _4 亞曱基雙環[31〇] 烷_2,6_二羧酸。步驟(a)產物(0.36·克,LO毫莫耳)於1 毛升T F A中攪拌1小時,濃縮並溶於5毫升τ η f中。反應以 IN NaOH凋整至ρΗ=13-14並攪拌2小時。反應混合物經 濃縮並以IN HC1調整至pH=l〇。所得物施加至陰離子交換 树脂(Bio-Rad® AG1_X8,以1Ν乙酸溶夢),得0.061克 (3 1 %)所需產物。FDMS : ΙνΓ+ 1 = 198。對 C9« 1 1 N〇4+0.25 當量H20之分析計算値:c,53.60; H,5.75; N,6.94。實測 値:C, 53·65; Η, 5.64; Ν, 6·85-。 · • 實例1 7 - (1 S *,2 S * , 5 R *,6 S * ) :2 -胺基-4 - (Ζ )-(二乙基亞磷羧基亞 甲基)雙環[3.1.0]己烷-2,6-二羧酸 (lS*,2S*,5R*,6S*)-2 -胺基’-4-(Ε):(二乙基亞磷羧基亞 / 甲基)雙環[3 . 1 . 0 ]己燒-2,6 -二幾酸
經濟部中央標準局員工消费合作社印製
(a)(lS*,2S*,5R*,6S*)-2-(N -第三丁 氧羰基)胺基-4-((E及Z卜二乙基亞磷羧基亞曱基‘)雙環[3 . 1 . 〇 ]己烷-2,6 _, -61 - 本纸張尺度適用中國標^T^NSyA4規枱(210X297公漦) 505623 經濟部中央標準局員工消费合作社印製 A7 59 ------ 五、發明説明() 一竣酸異構物A及B。使雙(三甲基矽烷基)醯胺鈉(2.丨毫莫 耳)在0°C添加至含亞甲基二膦酸四乙基酉旨(〇6克,2.1毫莫 耳)之無水曱笨溶液中而製備亞曱基二膦酸四乙基酯之鈉 鹽。此鈉鹽在0X:下快速添加至含實例5(a)產物(〇 5克, 1.4耄莫耳)之無水甲苯溶液中並攪拌1 5分鐘。使反應溫至 A概並攪拌至以T L C測定反應芜全。添加1 n H C1並使用乙 酸乙酯萃取反應混合物。合併之有機層以NaC1水溶液洗並 以MgS〇4脱水。氣縮有機相且粗產物使用hplc (EtOAc / 己烷)純化,得0.190克(2 8%)異構物八及〇119克(17%)異 構物B。 . 并構物A(E兴構物):FDMS : M+l=490。確實質量 値.對C22H36N09P : 490.2206。實測値:490.2202。異 構物 B(Z 異構物):FDMS : M‘+l二490。 (b)(lS ‘,28'511*,68”-2 -胺基- 4- (Z) -二乙基亞碍幾 基亞甲基雙環[^ · 1 · 〇 ]己燒_ 2,6 -二竣酸。步驟(a )產物異構 物A (0.15克,0.3〗毫莫耳)於2毫升tf A中攪拌i小時,濃 縮並溶於5毫升THF中。接著以2毫升1N Na〇H處理反應: 小時。濃縮反應混合物並以丨N HC1調整至p Η = 1 〇。所得物 施加至陰離子交換樹脂(Bi〇-Rad@ AG1-X8),以1N HC1溶 離並於ΙΟ中再結晶,得0.03克(27%)所需產物。fdms : 1^+卜,334 °對‘.〇1#2(^〇7? + 2.6當量}^1分析計算値:€:
36.48; Η,5·32; N, 3.27。實澍値:C,36.33; H,5 5〇; N 3.72 。 ’ ’ 依類似方法,分別自異構物B或·異構物〇起始製備其他兩 -62- 本纸張尺度適用中國國家標準(CMS ) A4規格(210X 297公浚) (請先閱讀背面之注意事項再填寫本頁} Φ 訂 505623 kl 117五、發明説明(6Q ) 種目的化合物。 實例1 8 , * I (lS*,2S*,5R*,6S*)-2 -胺基-4-亞磷羧基亞甲基雙環 [3 · 1 . 0 ]己烷-2,6 -二羧酸
(請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消费合作社印製 (a)(lS*,2S*,5R*,6S*)-2 -胺基-4-亞磷羧基亞曱基雙 環[3 . 1 . 0 ]己烷-2,6 -二羧酸。實例1 7 ( a)產物異構物A (0.1 5·克,0.31毫莫耳)於2毫升TFA中攪拌1小時並濃縮。 所得反應物以6N HC1回流處理隔夜,濃縮且所得產物分散 於H2〇及IP A中,得0.005克(5%)所需產物。FDMS : M—+ 1,278。 、 _ 實例1 9 (18*,25*,511*,68*)-2-胺基-4-2-氰亞甲基雙環[3.1.0] 己烷-2,6 -二羧酸 (18*,28*,511*,68*)-2-胺基-4 4-氰亞甲基雙環[3.1.0] 己烷-2,6 -二羧酸 -63- 本纸張尺度適用中國國家標準(CNS ) A4規格(210X 297公浼) 61505623 kl \¥1 五、發明説明()
(請先閲讀背面之注意事項再填寫本頁)
E Z 經濟部中央標準局員工消f合作社印製 (a)2-(N -弟二丁氧叛基)胺基-4-氣基亞曱基雙環[3 1 〇] 己烷- 2,6 -二羧酸(1S*,2S*,5R*,6S*)二乙酯異構物a及 B。藉0 °C下添加雙(三甲基矽龙基)醯胺鉀(2 · 6亳莫耳)至 含氰甲基膦酸二乙S旨(0.45克,2.6毫莫耳)之無水曱苯漆液 中而製備氰曱基膦酸二乙酯之鈉鹽。此鹽在〇 °C下快速添 加至含實例5 ( a )產物(〇 · 6克」1.7毫莫耳)中並攪拌1 5分 -鐘°使反應溫至室溫並欖拌直至以T L C測定反應完成。添 加IN .HC1並使用乙酸《乙酯萃取反應混合物。合併之.有機層 以NaC 1水溶液並以MgSΟ』脱水。濃縮有機相且粗產物使用 HPLC^EtOAc/己fe)純化,停〇·525克(82%)兩種異構物 之混合物。異構物A及B使用HPLC ( Et〇Ac /己烷)分離。 異構物A : M —+ 1 = 379。確實質量計算値對c19h26N2〇6 ( + H)二 3 79.1869。實測値:379.1875。 異構物 B ·· M —二 378。 ·' r (bKlS'SS'SR'GS*)-]—胺基_4-氰亞曱基雙環 [3 . 1 .0]己烷- 2,6 -二羧酸。步驟(a)產物異構物A(〇 15 克,0.39毫莫耳)於5毫升TF A中攪拌i小‘時,濃縮並溶於5 , -64- 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X 297公H ----一-- 505623 A7 B-7 五、 發明説明( 毛升THF中。反應再以5毫升1N Na〇H處理5小時。以I” HC1凋整反應至p H = 7並濃縮至乾·,所得固.體再構成於水中 並凋整至pH二10,施加至陰離子交換樹脂(Bi〇_Rad@ X8),以2N乙酸溶離,得〇 〇32克(36〇/〇)所需產物。 FDMS : M、l=223。對〇1(^1(^2〇4+〇 3當量 h2〇 分析計 算値:C, 52.77; H,4.69; N,12.31。實測値:C,52 53; H, 4.76; N, 12·17 。 . 實例2 0 — (1S*,2S*,4R*,5S*,6S*)_2-胺基雙環[3」〇]己烷-2,4,6 -三羧酸 二 . (請先閲諫背面之注意事項再填寫本頁) .«衣 , CO Η
c〇2h
'1T 經濟部中央標準局員工消f合作社印製 (a) 2 - (N -第二丁氧羰基)胺基_ 4 __氰基雙環[3 . j · ο ]己烷_ 2,6- — 4Sk(lS*,2S*,4R*,5S*,6S*)二乙酯。於含實例 8 (a)產物(1.45克,2.84毫莫耳)之無水二曱基亞颯(2〇毫升) 溶液中’添加氰化納(7〇〇毫克,5當量)且反應混合物在4 〇 °C攪拌4 8小時。/ 使反應混合物冷卻再倒入水卜200毫升)中。水相以乙醚萃 取3次且合併之乙醚萃取物以水洗及以硫酸鎂脱水。過濾 及眞空蒸發’得黃色牢沫(88〇毫克)。此扭產物於矽膠上層, / . -65.- ’ 本纸張尺度適用中國國家標率(CNS ) A4規格(210 X 297公及) V* 2 6 5 ο 5 經濟部中央標準局員工消f合作社印製 kl 13-7 - Q3 五、發明説明() 析(溶離液:乙醚2 5 % /己燒)純化,得透明膠狀之所需腈 ( 670毫克)。 lH NMR (300 MHz, CDC13, ^ ppm): 1.30 (6H,t, C〇2CH2(CH3 x 2),1.42 (9H,s,第三丁基),1.58 (1H,dd, C3-H), 2.10 (1H, dd,C6-H), 2.30 (2H,m,CVH + CVH),3.05 (1H,dd,C3-H),3.55 (1H,m,C4-H),4.20 (4H,m, -C02CiLCH3 x 2),5.40 (1H,s,NH)。 (b)(lS*,2S*,4R*,5R*,6S*)-2 -胺基雙環[3.1.0]己烷 -2,4,·6-三羧酸。步骤(a)產物(64毫克,0.175毫莫耳)與 2 Μ鹽酸(2毫升)之混合物在密封瓶中於9 0 °C加熱4 8小時。 冷卻後,反應混合物於眞空中蒸發得白色固體(8 Ό毫 克),其溶於最少量水中並以陽離子交換層析法(Dowex® 50X8- 1 00 :管柱依序以H2〇,H2〇:THF 1 : 1及再以 Η 2〇溶離。此胺基酸最後以Η 2〇:吡啶9 : 1溶離)而純 / 化。眞空中移除吡啶且殘留固體再溶於水中並凍乾、得絨 狀白色固體之所需胺基酸(3 8毫克)。m ρ〉3 00 °C。1H NMR (300 MHz,D2〇,β ppm) : 1·35 (1Η,dd,C3-H),1.65 (1Η, dd,C6-H),1·90 (1H,m, C5-H), 2.00 (2H,m, CrH + CyH), 3.18 (1H,m,C4-H)。 實例2 1 (lS*,2S*,4R*,6S*,6S*)-2 -胺基-4-氰基雙環[3.1.0]己 \ 規-2,6 -二幾酸 ·一 — (請先閱讀背面之注意事項再填寫本頁) 、-口 本纸張尺度適用中國國家標準(CNS ) A4規枋(210X 297公楚) 505623 經濟部中央標準局員工消費合作社印製 A7 —__________ B-7 64 ~ ------ 五、發明説明()
CN
/a)(lS*,2S*,4R*,5S*,6S*)-2-(N -第三丁 氧羰基)胺 基氰基雙環P 1 〇]己烷_2,6_二羧酸二於含實例2〇(a) 產物(200¾克,〇·55毫莫耳)之四氫呋喃(2亳升)溶液中添 加1莫耳當量氫氧化鋰溶液(丨· 2毫升)且混合物在室溫攪拌8 小時。 . 反應混合物以水稀釋,以1莫耳當量鹽酸酸化並以乙酸乙 Θ旨萃取3次。合併之有機萃取物以飽和氯化鈉溶液洗滌, 以MgS〇4脱水並眞空蒸發,得.白色玻璃狀物(18〇毫克)。 粗產物於碎膠上層析(溶離液乙酸乙酯5 %冰醋酸)純化, 得白色固體之所得二羧酸(12〇毫克)。 巾 NMR (300 MHz, DMSO-d6,β ppm) : 1.38 (9H,s,第 二丁基),1·58 (1H,dd, C3-H), 1.82 (1H, dd, C6-H),2·22 (1H, m, C5-H),2·36 (1H, m,CVH),2.60 (1H,dd,C3-H), 3.40 (1H, m,C4-H), 7.30 (1H,s, NH)。 (b)(lS*,2S*,4R*,5S*,6S*)-2-胺基-4-氰基雙環 [j . 1 . 0 ]己坑-2 气-一叛fe。步驟(a )產物(12 0毫克,〇. 3 8毫 莫耳)'溶於三氟乙酸(5毫升)单在室溫攪拌2小時。 反應混合物眞空蒸發,殘留物再溶於水中並眞空共沸得 白色固體(6 2毫克)。粗固體再溶於最少奎水中並以陽離子, -67;- 本紙張尺度適用^國國家標準(CNi) A4規栳(2丨0X 297公漦) ~ 一 ~~~ ^衣-- (請先閲讀背面之注意事項再填荇本頁) 、11 屬623 A7 五 、發明説明( 又換層析法(Dowex@ 50X8-100 ;管柱依序以H20,H2〇: T H F 1 : 1及再用H2 〇溶離,此芦基酸最後以h2 〇 :吡啶 9 : 1溶離)純化。眞空中移除吡啶且殘留固體再溶於水中 並;東乾,得絨狀白色固體之胺基酸(35毫克)。mp 240-242 。(:。 NMR (300 MHz, D20, ^ ppm) : 1·85 (1H,dd,C3-H), 2·21 (1H, t, C6-H), 2.42 (1H? dd, C^H), 2.60 (2H, m, G3-H + C5-H),3.83 (1H,m, C4-H )。 _ 實例2 2 (1 S *,2 S *,4 R * , 5 S *,6 S * ) - 2 -胺基:4 -羧醯胺雙環[3 . 1.0 ] 己烷-2,6 _二羧酸 — (請先閱请背面之注意事項再填寫本頁)
經濟部中央標隼局員工消費合作社印製 (3)(18*.23*,411*,58*,65*)-2-(1^第三丁氧羰基)胺 基-4-羧醯胺雙環[3·〗0]己烷-2,6_二羧酸。在〇_5Ό下, 於含實例2 0 ( a )產物(Μ5毫克,0.40毫莫耳)之絕對乙醇(1 毫升)溶液中添加^1)30%過氧,化氫(〇]57毫升),(2)61^氫 氧化鈉(0.20毫升)。使反應-混^合物溫至室溫並再攪拌4小 時,其以更多水(4毫升)稀釋。 7 2小時後,反應混合物以2 M鹽酸酸化,並以乙酸乙酯萃, -68- 本纸張尺度適用中國國家標準(CNS ) Λ4規格(210X 297公趁) 505623 A7 1^7 經濟部中央標準局員工消f合作社印製 五、發明説明( 取3次。合併之有機萃取物以飽和氯化鈉溶液洗,以 脱水、過濾並眞空蒸發,得白色固體(84毫克)。粗產物於 石夕膠上層析(溶離液乙酸乙酯5 %冰醋酸)純化,得白色固體 之所f酸(34毫克)。 /H NMR (300 MHz,DMSO-d6,β ppm) ·· 1.42 (9H,s 第 三丁基),1.65 (1H,dd,c3-H),^75 (1H,寬,s,c6-H),2 〇8 (2H,m,CVH + C3-H),2.14 (1H,m,C5_H),丄 i〇 (1H, H),6.90 (1H,s,NH),7·44 (1H,s,NH),7 64 (m, s,nh), 12.35 (2H,寬峰,2 X C〇2H)。 (匕)(18*,28*,411*,5 5*,63^)-2-胺基-4_羧醯胺雙環 [3.1.0]己烷-2,6_二羧酸。步驟(a)產物(34毫克,〇 j亳 莫耳)於三氟乙酸(5毫升)之溶液在室溫攪拌2小時。 反應混合物再眞空蒸發至乾,再溶於水中並在7〇χ:眞空 共沸。此粗固體溶於最少量水中並以陽離子交換層析= (D〇WeX@ 5〇X8-10〇 :管柱依序以 H2〇,H2〇 : THF 1,\ 再以溶離,此胺基酸最後以H2〇 :吡啶9 ·· 1溶離)純 化。眞空中移〜除,比淀,且殘留固體再溶於水中並康乾,得 絨狀白色固體之所需胺基酸(12毫克),mp 260_262 τ(分 解)H NMR (』〇 MHz,d2〇, β ppm) : i 95 (1Η,杖 Η), 2.^0 (1H, d, C6-H), 2.42-2.64 (3H, m, C!-H + C3-H+C5- H),3.78 (1 H, rn, /C4-H )。 丨> — !0l„ (請先閲讀背面之注意事項再填寫本頁j
、1T -69 -
Claims (1)
- 505623 A8 B8 …—jQS·__ D8 91. 3. 斗月 申請專利範圍 公营修正ΜΛ, 1. 一種下式之化合物 其中:NH R1 代表 OH,P〇3H2, OCH3, F,NH2, N3, NHAC,NHCOPh, HNS02CH3,NHi 0 IIπ iC『CH3, C02H,CN 及 hNH2 且 R2 代表 H ’或 R1 與 R2 合而代表=0, =N-OH,=CHC02H,=CH2, =CH-P03Et2,CH-P〇3H2 及=CH-CN。 或其無毒性易代謝酯或醯胺;或其醫藥可接受性鹽。 2·根據申請專利範圍第1項之化合物,其中: 〇 R1 代表 F,〇H,0CH3,NH2,NHAC,NHCOPh,-顺2,N^/ ,CN或P〇3H2且R2代表氫,或R1與R2合而代表=0, =N〇H,或=CH2。 3·根據申請專利範圍第1項之化合物,其中:R1 代表N3、NHC0NHCH3或 NHS02CH3 ;或 R1 及 R2 合而代表=CHC00H、=CHP03H = CHP03(C2H5)2 或= CHCN。 O:\52\52725-910329.DOC\ 本紙張尺度適用中國國家標準(CNS) A4規格(210 χ 297公釐) 505623 8 8 8 8 A B c D 々、申請專利範圍 4. 根據申請專利範圍第1項之化合物,係選自 (lS*,2S*,5R*,6R*)-2 -胺基-4-氧代雙環[3.1.0]己 烷-2,6-二羧酸; (lS*,2S*,5R*,6R*)-2 -胺基-4-[反]-羥亞胺雙環 [3.1.0] 己烷-2,6 -二羧酸; (lS*,2S*,5R*,6R*)-2 -胺基-4-[順]-羥亞胺雙環 [3 · 1 · 0 ]己烷-2,6 -二羧酸; (lS*,2R*,4S*,5S*,6S*)-2-胺基-4-氟雙環[3.1.0] 己烷-2,6-二羧酸; (lS*,2S*,5R*,6R*)-2-胺基-4-Z-羧亞甲基雙環 [3.1.0] 己烷-2,6 -二羧酸;及 (18*,23*,511*,611*)-2-胺基-4-亞甲基雙環[3.1.0] 己垸-2,6 -二竣酸。 5. —種製備根據申請專利範圍第1至4項中任一項之化合物 之方法,包括: (a)使下式化合物或其鹽水解:其中R11代表氫原子或醯基及R12代表羧基或酯化羧基; (b)使下式化合物或其鹽水解: O:\52\52725-910329.DOC\ 5 - 2 - 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 505623 A8 B8 C8 D8 六、申請專利範圍其中R13代表羧基或酯化羧基,及R14及R15各獨立代表氫 原子、(C2_6)烷醯基、(Cu)烷基、(C3-4)烯基或苯基 (C^4)烷基其中苯基為未取代或經鹵素(Ci.4)烷基或 (Ci-4)烷氧基取代;或 (c)使下式化合物或其鹽脫保護:其中R18代表氫原子或氮保護基及R!6及rP各獨立代表氫 原子或羧基保護基; 隨後,若需要及/或需要: (i)溶解式I化合物; (η)使式I化合物轉化成其非毒性易代謝酯或醯胺;及/ 或 本紙浪尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 505623 A B c D 、申請專利範圍 (i i i)使式I化合物或其非毒性易代謝酯或醯胺轉化成其 醫藥可接受性鹽。 6. 根據申請專利範圍第1項之化合物,係用以製造用於調節 代謝營養穀氨酸受體功能之醫藥。 7. —種下式化合物或其鹽: ΗII 及Rl及r2如申請專利範圍第1項之定義 8· —種下式之化合物或其鹽: KIII 其中R13代表羧基或酯化羧基,及RM&R15各獨立代表J 原子、(C 2 . 6 )烷醒基、(C丨.4 )烷基、(C 3 _ 4 )烯基或苯J (Ci.4)烷基其中苯基為未取代或經自素(Ci4)烷基^ -4- O:\52\52725-910329. DOC\ 本紙張尺度適用中國國家標準(CNS) A4規格(210 x 297公董) 505623 8 8 8 8 A B c D 、申請專利範圍 ((^_4)烷氧基取代;及R1及R2如申請專利範圍第1項之 定義。 9. 一種下式之化合物或其鹽: RR c〇2rj IV 其中R18代表氫原子或氮保護基及R16及R17各獨立代表氫 原子或羧基保護基;及R1與R2如申請專利範圍第1項之 定義。 O:\52\52725-910329.DOC\ 5 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4701197P | 1997-05-14 | 1997-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW505623B true TW505623B (en) | 2002-10-11 |
Family
ID=21946570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW087107483A TW505623B (en) | 1997-05-14 | 1998-05-14 | Excitatory amino acid receptor modulators |
Country Status (30)
Country | Link |
---|---|
US (3) | US5958960A (zh) |
EP (1) | EP0878463B1 (zh) |
JP (1) | JP4191263B2 (zh) |
KR (1) | KR20010012489A (zh) |
CN (1) | CN1125807C (zh) |
AR (1) | AR015664A1 (zh) |
AT (1) | ATE198190T1 (zh) |
AU (1) | AU729632B2 (zh) |
BR (1) | BR9808787A (zh) |
CA (1) | CA2289472C (zh) |
CO (1) | CO4950558A1 (zh) |
DE (1) | DE69800430T2 (zh) |
DK (1) | DK0878463T3 (zh) |
EA (1) | EA199901029A1 (zh) |
ES (1) | ES2152738T3 (zh) |
GR (1) | GR3035156T3 (zh) |
HU (1) | HUP0001404A3 (zh) |
ID (1) | ID23183A (zh) |
IL (1) | IL132894A0 (zh) |
NO (1) | NO995480L (zh) |
NZ (1) | NZ500954A (zh) |
PE (1) | PE73599A1 (zh) |
PL (1) | PL336793A1 (zh) |
PT (1) | PT878463E (zh) |
SI (1) | SI0878463T1 (zh) |
SV (1) | SV1998000056A (zh) |
TR (1) | TR199902777T2 (zh) |
TW (1) | TW505623B (zh) |
WO (1) | WO1998051655A1 (zh) |
ZA (1) | ZA983930B (zh) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA983930B (en) * | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
US6316498B1 (en) * | 1998-01-28 | 2001-11-13 | Taisho Pharmaceutical Co., Ltd. | Fluorine-containing amino acid derivatives |
ATE269293T1 (de) * | 1998-08-31 | 2004-07-15 | Taisho Pharmaceutical Co Ltd | 6-fluoro(3.1.0)hexan-derivate |
PE20001236A1 (es) * | 1998-11-13 | 2000-11-10 | Lilly Co Eli | Moduladores del receptor de aminoacidos excitadores |
EP1142860B1 (en) * | 1998-12-18 | 2004-08-11 | Taisho Pharmaceutical Co. Ltd. | Intermediates and process for producing fluorine-containing amino acid compound by using the same |
CA2630009C (en) | 1999-03-25 | 2010-04-20 | Taisho Pharmaceutical Co. Ltd. | Novel carboxylic acid derivatives and process for producing the same |
JP4505926B2 (ja) * | 1999-03-25 | 2010-07-21 | 大正製薬株式会社 | 新規カルボン酸誘導体及びその製造方法 |
ATE298343T1 (de) | 1999-04-28 | 2005-07-15 | Univ Georgetown | Ligande für metabotropische glutamat-rezeptoren |
US6528499B1 (en) | 2000-04-27 | 2003-03-04 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
US6417366B2 (en) | 1999-06-24 | 2002-07-09 | Abbott Laboratories | Preparation of quinoline-substituted carbonate and carbamate derivatives |
JP4783967B2 (ja) * | 1999-07-21 | 2011-09-28 | 大正製薬株式会社 | 含フッ素アミノ酸誘導体を有効成分とする医薬 |
EP1246797B1 (en) * | 1999-12-08 | 2008-07-23 | Eli Lilly And Company | Cyclopentyl sulfonamide derivatives |
US6639107B1 (en) | 1999-12-08 | 2003-10-28 | Eli Lilly And Company | Cyclopentyl sulfonamide derivatives |
EP1351925A1 (en) * | 2001-01-11 | 2003-10-15 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
HUP0400620A3 (en) * | 2001-01-11 | 2012-09-28 | Lilly Co Eli | Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds |
WO2002068380A1 (en) * | 2001-02-22 | 2002-09-06 | Eli Lilly And Company | Synthetic excitatory amino acids |
CA2471642C (en) * | 2001-12-27 | 2011-05-24 | Taisho Pharmaceutical Co., Ltd. | 6-fluorobicyclo[3.1.0]hexane derivatives |
US20040116489A1 (en) * | 2002-02-12 | 2004-06-17 | Massey Steven Marc | Synthetic excitatory amino acids |
US20050192273A1 (en) * | 2002-04-03 | 2005-09-01 | Johnson Bryan G. | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
AU2003232146B2 (en) * | 2002-06-11 | 2009-06-18 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
EP2287147B1 (en) | 2003-06-26 | 2013-05-15 | Taisho Pharmaceutical Co., Ltd. | 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative |
JP4984529B2 (ja) | 2003-06-26 | 2012-07-25 | 大正製薬株式会社 | 2−アミノビシクロ[3.1.0]ヘキサン−2,6−ジカルボン酸誘導体 |
ES2355144T3 (es) | 2003-06-26 | 2011-03-23 | Taisho Pharmaceutical Co., Ltd. | Derivado de éster 2-aminobiciclo 3.1.0 hexano-2,6-dicarboxílico. |
US7786314B2 (en) * | 2003-11-07 | 2010-08-31 | Taisho Pharmaceutical Co., Ltd | Processes for preparing bicyclo [3.1.0] hexane derivatives, and intermediates thereto |
US20070043100A1 (en) | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
US20070082940A1 (en) * | 2005-07-27 | 2007-04-12 | Phil Skolnick | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US20080045725A1 (en) * | 2006-04-28 | 2008-02-21 | Murry Jerry A | Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane |
WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
BRPI0716604A2 (pt) | 2006-09-08 | 2013-04-09 | Braincells Inc | combinaÇÕes contendo um derivado de 4-acilaminopiridina |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US8138377B2 (en) * | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
US20080269348A1 (en) * | 2006-11-07 | 2008-10-30 | Phil Skolnick | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use |
WO2008058192A2 (en) | 2006-11-08 | 2008-05-15 | Molecular Insight Pharmaceuticals, Inc. | Heterodimers of glutamic acid |
EP2073799A4 (en) * | 2007-03-12 | 2009-08-19 | Vm Discovery Inc | NOVEL ACTIVE SUBSTANCES FROM CALCIUMIONAL CHANNEL MODULATORS |
WO2008153937A2 (en) * | 2007-06-06 | 2008-12-18 | Dov Pharmaceutical, Inc. | Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
EP2679570A3 (en) * | 2008-05-21 | 2014-07-02 | Taisho Pharmaceutical Co., Ltd. | Method of producing bicyclo[3.1.0]hexane derivative |
WO2010065899A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
WO2010111080A2 (en) | 2009-03-27 | 2010-09-30 | Eli Lilly And Company | Optimized treatment of schizophrenia |
BR112012000210A2 (pt) | 2009-06-15 | 2019-09-24 | Molecular Insight Pharm Inc | processo para a produção de heterodímeoros de ácido glutâmico. |
JO2978B1 (en) | 2009-12-21 | 2016-03-15 | ايلي ليلي اند كومباني | MGLU2 aids |
KR101554793B1 (ko) * | 2010-11-18 | 2015-09-21 | 일라이 릴리 앤드 캄파니 | mGluR 2/3 길항제로서의 4-치환된-3-벤질옥시-비시클로[3.1.0]헥산 화합물 |
AR083845A1 (es) * | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
US9296710B2 (en) | 2011-06-17 | 2016-03-29 | Eli Lilly And Company | Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist |
CA2860504A1 (en) | 2012-01-06 | 2013-07-11 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix |
AR089718A1 (es) | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
US9447121B2 (en) | 2013-01-14 | 2016-09-20 | Molecular Insight Pharmaceuticals, Inc. | Triazine based radiopharmaceuticals and radioimaging agents |
FR3050021B1 (fr) | 2016-04-06 | 2018-10-19 | Nitrates & Innovation | Ensemble de deux reservoirs prets a etre assembles par vissage pour former une cartouche d'explosif bi-composant |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3325095A (en) * | 1994-08-12 | 1996-03-07 | Eli Lilly And Company | Composition and method for protection against drug dependency |
WO1996004901A1 (en) * | 1994-08-12 | 1996-02-22 | Eli Lilly And Company | Composition and method for treating anxiety |
US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
PL182285B1 (pl) * | 1994-08-12 | 2001-12-31 | Lilly Co Eli | Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL |
IL118727A (en) * | 1995-06-29 | 2003-01-12 | Lilly Co Eli | (-)-2-spiro-5-hydantoinbicyclo [3.1.0] hexane-6-carboxylic acid, salts thereof and use thereof for the preparation of (+)-(2) aminobicyclo [3.1.0] hexane-2,6-dicarboxylic acid |
ZA969485B (en) | 1995-11-16 | 1998-05-12 | Lilly Co Eli | Excitatory amino acid receptor antagonists. |
GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
US5912248A (en) | 1995-11-16 | 1999-06-15 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
ZA983930B (en) * | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
-
1998
- 1998-05-08 ZA ZA9803930A patent/ZA983930B/xx unknown
- 1998-05-12 CO CO98026351A patent/CO4950558A1/es unknown
- 1998-05-13 PT PT98303730T patent/PT878463E/pt unknown
- 1998-05-13 SI SI9830021T patent/SI0878463T1/xx unknown
- 1998-05-13 DK DK98303730T patent/DK0878463T3/da active
- 1998-05-13 AT AT98303730T patent/ATE198190T1/de not_active IP Right Cessation
- 1998-05-13 US US09/078,337 patent/US5958960A/en not_active Expired - Lifetime
- 1998-05-13 DE DE69800430T patent/DE69800430T2/de not_active Expired - Lifetime
- 1998-05-13 ES ES98303730T patent/ES2152738T3/es not_active Expired - Lifetime
- 1998-05-13 EP EP98303730A patent/EP0878463B1/en not_active Expired - Lifetime
- 1998-05-13 AR ARP980102224A patent/AR015664A1/es active IP Right Grant
- 1998-05-14 PL PL98336793A patent/PL336793A1/xx unknown
- 1998-05-14 HU HU0001404A patent/HUP0001404A3/hu unknown
- 1998-05-14 TW TW087107483A patent/TW505623B/zh active
- 1998-05-14 AU AU73869/98A patent/AU729632B2/en not_active Ceased
- 1998-05-14 CA CA002289472A patent/CA2289472C/en not_active Expired - Fee Related
- 1998-05-14 SV SV1998000056A patent/SV1998000056A/es unknown
- 1998-05-14 IL IL13289498A patent/IL132894A0/xx unknown
- 1998-05-14 WO PCT/US1998/009862 patent/WO1998051655A1/en not_active Application Discontinuation
- 1998-05-14 JP JP54954398A patent/JP4191263B2/ja not_active Expired - Fee Related
- 1998-05-14 TR TR1999/02777T patent/TR199902777T2/xx unknown
- 1998-05-14 PE PE1998000370A patent/PE73599A1/es not_active Application Discontinuation
- 1998-05-14 ID IDW991344A patent/ID23183A/id unknown
- 1998-05-14 KR KR1019997010444A patent/KR20010012489A/ko not_active Application Discontinuation
- 1998-05-14 NZ NZ500954A patent/NZ500954A/en unknown
- 1998-05-14 EA EA199901029A patent/EA199901029A1/ru unknown
- 1998-05-14 BR BR9808787-8A patent/BR9808787A/pt active Search and Examination
- 1998-05-14 CN CN98804992A patent/CN1125807C/zh not_active Expired - Fee Related
-
1999
- 1999-05-28 US US09/322,651 patent/US6160009A/en not_active Expired - Lifetime
- 1999-11-09 NO NO995480A patent/NO995480L/no not_active Application Discontinuation
-
2000
- 2000-08-11 US US09/637,143 patent/US6268507B1/en not_active Expired - Lifetime
- 2000-12-27 GR GR20000402844T patent/GR3035156T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW505623B (en) | Excitatory amino acid receptor modulators | |
JP6609060B2 (ja) | 置換ピペリジン化合物およびその用途 | |
EP1000927B1 (en) | Excitatory amino acid receptor modulators | |
TW509667B (en) | Bicyclo [2.2.1] heptanes and related compounds | |
EP1565429B1 (en) | Diaryl ureido derivatives and their medical use | |
RO119147B1 (ro) | Aminoacizi biciclici, procedeu pentru prepararea acestora, intermediari şi compoziţie farmaceutică | |
EA006396B1 (ru) | Конденсированные бициклические аминокислоты | |
KR20050058367A (ko) | 피리미딘 유도체 및 그의 cb2 조절제로서의 용도 | |
TW201215605A (en) | Manufacturing process for pyrimidine derivatives | |
NZ522674A (en) | Novel spiro[2.4]heptane amino carboxy compounds and derivatives thereof | |
GB2355982A (en) | Heterocyclic amino acids | |
EA001769B1 (ru) | Антагонисты рецепторов возбудительной аминокислоты | |
DE69635886T2 (de) | Exzitatorisch wirkende Aminosäurederivate | |
EP0781271B1 (en) | Benzocycloalkene compounds, their production and use | |
JP2018535926A (ja) | ピリジン又はピリミジン誘導体 | |
KR20200035077A (ko) | 통증 및 통증 관련 상태 치료를 위한 새로운 프로판아민 유도체 | |
JP4984529B2 (ja) | 2−アミノビシクロ[3.1.0]ヘキサン−2,6−ジカルボン酸誘導体 | |
JP2002520406A (ja) | ビシクロヘキサン誘導体 | |
CN116234552A (zh) | mGluR5和5-HT2A受体的双重调节剂及其用途 | |
TW201206910A (en) | Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof | |
JP2004524292A5 (zh) | ||
TW201130811A (en) | Aryl benzylamine compounds | |
EP3526201B1 (en) | Imidazole compounds as eaat3 inhibitors | |
JP2007063129A (ja) | 2−アミノ−3−アルコキシビシクロ[3.1.0]ヘキサン誘導体 | |
TW422836B (en) | Excitatory amino acid derivatives |